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Background BIG 3-07/TROG 07.01 is an international randomised trial evaluating tumour bed boost 
(TBB) and hypofractionation in non-low risk ductal carcinoma in situ (NLR-DCIS) following breast 
conserving surgery and whole breast radiotherapy (WBRT). The purpose of this paper is to report the 
effects of diagnosis and treatment of  health-related quality of life (HRQL) to two years.  
Methods BIG 3-07/TROG 07.01 is a multicentre parallel randomised controlled unblinded trial. 
Recruitment setting was 118 hospitals in 11 countries. Women aged ≥18 years with completely 
excised non-low risk DCIS were randomised, unblinded, using a minimisation algorithm, to TBB (16 
Gy in 8 fractions over 1.5 weeks) or no TBB, following conventional WBRT (50 Gy in 25 fractions over 
5 weeks) or hypofractionated WBRT (42.5 Gy in 16 fractions over 3.5 weeks). Stratification factors 
were age, planned endocrine therapy and treating centre. The primary endpoint, time to local 
recurrence, will be reported when participants have completed 5 years of follow-up. The proposal to 
report the HRQL data at 2 year follow-up was approved by the Data and Safety Monitoring 
Committee 23/10/2015. The HRQL statistical analysis plan pre-specified eight aspects of HRQL, 
assessed by four questionnaires at baseline, end of treatment (EOT), and 6, 12 and 24 months after 
radiotherapy: fatigue, physical functioning (EORTC QLQ-C30); cosmetic status, breast-specific 
symptoms, arm/shoulder-related functional status (Breast Cancer Treatment Outcome Scale, 
BCTOS); body image and sexuality (Body Image Scale, BIS); perceived risk of invasive breast cancer 
(Cancer Worry Scale, CWS and a study-specific question). For each of these, TBB was compared with 
no TBB, and conventional with  hypofractionated WBRT, using generalised estimating equation 
models, by intention-to-treat, with Hochberg adjustment for multiple testing. This trial is registered 
with ClinicalTrials.gov, number NCT00470236. 
Results Between 1 June 2007 and 14 August 2013, 1208 women were enrolled and randomly 
assigned to receive no TBB (n=605) or TBB (n=603); 396 women were  randomised between 
conventional (n=188) and hypofractionated WBRT (n=189). All these patients were followed up at 
two-year for this analysis. Most patients received their allocated treatment (1098/1208, 91%), and 
most completed their scheduled HRQL assessments  (1147/1208, 95% at baseline; 988/1141, 87% 
still on study at two years). Patients with HRQL assessments at baseline and ≥1 other time point were 
analysed: QLQ-C30, n=1147; BCTOS, n=920; BIS, n=919; CWS, n=908; study-specific risk question, 
n=878. Cosmetic status was worse with TBB compared with no TBB across all time-points (global p 
value =0.0001, Hochberg-adjusted p=0.002); at EOT, the estimated difference between TBB and no 
TBB  [95% confidence intervals] was 0.13 [0.06, 0.20], p=0.00021, persisting at 24 months (0.13 [0.06, 
0.20], p=0.00021). Arm/shoulder function was also adversely affected by TBB (global p value =0.0033, 
Hochberg adjusted p=0.045); the difference between TBB and no TBB  at EOT was 0.08 [0.01, 0.15], 
p=0.021), but considerably smaller at 24 months (0.04 [-0.03, 0.11], p=0.29). None of the other pre-
specified aspects of HRQL differed significantly after adjustment for multiple testing: estimated 
differences between TBB and no TBB at EOT were: fatigue 1.49 [-0.81, 3.80], p=0.20; physical 
functioning -1.60 [-2.95, -0.24],p=0.021; breast-specific symptoms 0.15 [0.06, 0.25], p=0.002; body 
image/sexuality 0.22 [-0.22, 0.66), p=0.33]; CWS -0.14 [-0.38, 0.10], p=0.24), study-specific question 
about perceived risk of invasive breast cancer -0.11 [-0.23, 0.01], p=0.07.  
Interpretation TBB was associated with persistent adverse impacts on cosmetic status and 
arm/shoulder functional status, which may inform shared decision making while local recurrence 
analysis is pending.  
Funding National Health and Medical Research Council (Grant numbers: APP1099860, APP454390), 
Susan G. Komen for the Cure® (OG12-BIG), Breast Cancer Now (2017NOVPR990), OncoSuisse 
(KLS/KFS 02527-02-2010), Dutch Cancer Society (KWF 2009-4467). 
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RESEARCH IN CONTEXT 
 
Evidence before this study 
We searched five electronic databases: MEDLINE; PsycInfo; CINAHL; EMBASE; and Scopus from 
database inception to 12 November 2015. Our search strategy comprised a comprehensive set of 
terms for “DCIS” and “PROs” (for full list of search terms, see online Appendix A of King et al, 2017). 
No language restrictions were applied. We also searched the reference lists of all studies included in 
this review and of other relevant systematic reviews, conducted an electronic search by author of 
key researchers identified, and contacted experts in the field (identified by our team) to enquire 
about ongoing studies. We identified 19 papers that reported PROs from 13 studies. These were 
assessed for research quality against 21 quality assessment criteria (see online Appendix B of King et 
al, 2017); quality scores ranged from 19% to 69%. There were no prior meta-analyses or data from 
randomised trials examining PROs in patients with DCIS. Further, the quality of evidence about the 
impact of DCIS treatments on PROs was limited by the design, analysis and reporting of the studies. 
The systematic review highlighted the need for adequately powered PRO studies to assess the acute 
impacts, recovery trajectories and long-term deficits of contemporary treatments for DCIS.  
 
Added value of this study 
This substudy of the randomised phase III BIG 3-07/TROG 07.01 trial investigated the effects of 
tumour bed boost (TBB) and hypofractionation on PROs to two years after treatment in women with 
non-low risk DCIS treated with breast conserving surgery and whole breast radiotherapy (WBRT). To 
our knowledge, this is the largest prospective study of PROs in women with DCIS. Our study showed 
that TBB had a detrimental effect on patient-reported cosmetic outcomes and arm and shoulder 
functional status. The adverse effect of TBB on perceived cosmetic status persisted at 24 months 
whereas the effect on arm and shoulder function resolved by 24 months. These adverse effects of 
TBB were generally worst at the end of radiotherapy and improved over time. In contrast, adverse 
impacts of TBB on role, social and physical functioning were small and transient. TBB was not 
significantly associated with body image or perceived risk of invasive breast cancer. However, body 
image was markedly worse with conventionally fractionated WBRT than hypofractionated WBRT, and 
there was a cumulative adverse impact of radiotherapy on arm and shoulder functional status for 
women who received TBB after conventional WBRT.  
 
Implications of all the available evidence 
Our results provide the first body of evidence on the trajectories of impact and recovery from local 
therapies in patients with DCIS of the breast. Pending efficacy analysis of the effects of TBB and 
WBRT dose-fractionation on time to local recurrence, the primary study endpoint of BIG 3-07/TROG 
07.01 trial, the PROs data presented in this report would support shared treatment decision making 
in DCIS for patients and clinicians. 
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The impacts of treatment for invasive breast 
cancer on health-related quality of life (HRQL) are 
well documented.(1) In contrast, there is little 
evidence for women diagnosed with ductal 
carcinoma in situ (DCIS) of the breast. A systematic 
review of HRQL and patient-reported outcomes 
(PROs) after treatment for DCIS identified 23 
papers reporting 17 studies, none of which was a 
RCT.(2)  
Under the auspices of the Breast 
International Group (BIG) and led by the Trans-
Tasman Radiation Oncology Group (TROG), BIG 3-
07/TROG 07.01 is an international phase III RCT 
evaluating tumour bed boost (TBB) and whole 
breast radiotherapy (WBRT) dose fractionation 
schedules for women with non-low risk DCIS 
treated with breast conserving therapy.(3) The 
primary endpoint, time to local recurrence, will be 
reported when participants have completed 5 
years of follow-up. A HRQL substudy provides 
patients’ perspectives to complement the primary 
endpoint.   
This paper reports PROs from baseline to 
two years after radiotherapy (RT). The primary 
objective of the BIG 3-07/TROG 07.01 HRQL 
substudy was to evaluate the impacts of TBB and 
WBRT dose-fractionation on key PROs that affect 
HRQL. Secondary objectives were to document 
longitudinal PRO changes, and assess variations in 
baseline PROs between the four participating 
geographic regions (Australia, New Zealand and 
Singapore (ANZS)); Canada; United Kingdom [UK] 
and Ireland; and western Europe 
(Netherlands,Belgium, France, Switzerland).  
 
Methods 
Study design and participants 
BIG 3-07/TROG 07.01 is an multicentre 
parallel randomised controlled unblinded trial for 
patients with non-low risk DCIS. Clinical and/or 
pathologic markers for increased risk of local 
recurrence include young age (<50 years), or in 
patients aged ≥50 years, the presence of one or 
more of the following: symptomatic presentation, 
palpable tumour, microscopic tumour size ≥15 
mm, multifocal disease, intermediate/high nuclear 
grade, central necrosis, comedo histology, radial 
surgical margin <10 mm. Women ≥18 years with 
non-low risk DCIS treated by breast conserving 
surgery and planned for post-operative WBRT were 
eligible for randomisation to receive TBB (16 Gy in 
8 fractions over 1.5 weeks) or no TBB, following 
WBRT. All patients provided written informed 
consent before study enrolment. Ethics 
Committees or institutional review boards at each 
site approved the study protocol. Protocol 
amendments enabled international expansion by 
introducing three randomisation categories (27 
August 2007) and increased the sample size from 
610 to 1600 (21 December 2011). All amendments 
were approved by the relevant ethics committees.  
 
Randomisation and masking 
Prior to study activation, each centre 
elected to participate in one of three 
randomisation categories (Figure A). Category A 
was a 4-arm randomisation of TBB vs no TBB 
following WBRT, and conventional WBRT (50 Gy in 
25 fractions over 5 weeks) vs hypofractionated 
WBRT (42.5 Gy in 16 fractions over 3.5 weeks)). 
Categories B and C were 2-arm randomisations 
betweenTBB vs no boost following conventional or 
hypofractionated WBRT, respectively.  
Centralised electronic registration and 
randomisation was provided through a web based 
operating system, hosted on the University of 
Adelaide’s Data Management and Analysis Centre 
(DMAC) website. Randomisation was done by 
dynamic allocation, using a minimisation algorithm 
generated by  the Centre for Biostatistics and 
Clinical Trials, Melbourne, Victoria, Australia. 
Stratification factors were age at diagnosis (< 50 
years, ³ 50 years), planned endocrine therapy (yes, 
no) and treating centre. Neither patients nor 
treating staff were masked to treatment allocation. 
 
Procedures 
All patients received WBRT which was 
administered once daily within 12 weeks of the last 
breast surgical procedure.  No dose modification or 
treatment interruption was permitted, as per the 
protocol.  Computer tomography (CT)-based RT 
planning was mandatory.  The WBRT was delivered 
using tangential photon beams with wedges or 
sub-fields to optimise dose homogeneity. The 
number of treatment visits required ranged from 
16 (hypofractionated WBRT [42.5 Gy in 16 
fractions], no TBB) to 33 (conventionally 
fractionated WBRT [50 Gy in 25 fractions] plus TBB 
[16 Gy in 8 fractions]). TBB, if allocated, was given 
after WBRT to the primary tumour site using an 
incident electron beam or megavoltage photons 
via tangential or other field arrangements that 
conformed to protocol-specified dose 
homogeneity and normal tissue constraints. 
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Interstitial brachytherapy was not permitted.  The 
use of bolus over the treated breast to increase 
skin dose and regional nodal irradiation were also 
not permitted. BIG 3-07/TROG 07.01 included an 
RT quality assurance programme. Adjuvant 
endocrine therapy use was at the discretion of the 
treating clinicians, and chemotherapy use was 
prohibited.  
Patients were followed up 3-6 monthly for 
three years after RT, and annually for a total of 10 
years. Bilateral mammogram was performed one 
year after the pre-treatment mammogram and 
then annually. Patients with protocol eligibility 
violation would be excluded from main analysis of 
the randomised trial. All reported local recurrence 
events were centrally reviewed based on source 
documents. Serious adverse events including grade 
4 or 5 acute or late morbidity were reported from 
the time of study registration until 30 days after 
the last RT fraction independent of whether they 
were protocol therapy-related. Adverse events and 
overall study conduct were reviewed by the Trial 
Steering Committee at least six monthly during the 
accrual phase and then annually, and monitored by 
the Data, Safety and Monitoring Committee at 
least annually.   
Health-related quality of life assessment 
HRQL was assessed prior to randomisation 
(baseline), at the end of RT (EOT) and at 6, 12, 24, 
60 and 120 months after RT, and were 
administered during clinic attendances. HRQL was 
assessed using several well-validated self-reported 
questionnaires, listed below in relation to eight key 
PROs (italisicised) of particular relevance in this 
trial. At European Organisation for Research and 
Treatment of Cancer (EORTC sites), only the EORTC 
QLQ-C30 was administered. Reasons for non-
completion were recorded by site staff.   
Fatigue and physical functioning were 
assessed with the European Organisation for 
Research and Treatment of Cancer core quality of 
life questionnaire (EORTC QLQ-C30), which is valid 
in breast cancer.(4) Following EORTC scoring 
algorithms, scales ranged 0-100.(5) A high score for 
physical function represented a high level of 
function (similarly for global health status/QOL and 
other functional scales); whilst for fatigue (and 
other symptoms) a high score for a symptom scale 
indicated a high symptom burden.  
Perceived cosmetic outcome was evaluated 
using the Breast Cancer Treatment Outcome Scale 
(BCTOS), yielding three subscales: breast-specific 
cosmetic status (BCTOS -CS), arm and shoulder-
specific functional status (BCTOS -FS) and breast-
specific symptoms BCTOS (-BSS),(6) each ranging 1-
4. The 22 BCTOS questions ask about the perceived 
degree of difference between the treated versus 
untreated breast, with higher scores indicating 
greater asymmetry.  
Body image and sexuality was assessed 
using the Body Image Scale (BIS).(7) The 10 items 
were summed to produce an overall summary 
score, ranging 0-30, with higher scores indicating 
worse body image and sexuality. BCTOS and BIS 
were both validated instruments for breast cancer.  
Perceived risk of invasive breast cancer was 
assessed in two ways. First, using the Cancer Worry 
Scale (CWS),(8) modified with permission of the 
CWS authors by replacing the term “cancer” with 
“invasive cancer”. The four items were summed to 
produce an overall score ranging 0-16, higher 
scores indicating more cancer worry. Second, with 
a study-specific question: “In your opinion, 
compared with other women your age who have 
had DCIS, what are your chances of getting invasive 
breast cancer?”, based on a question used 
previously.(9, 10) There were five response 
options: much lower (1); somewhat lower (2); the 
same (3); somewhat higher (4); a lot higher (5). 
 
Two additional questionnaires, the Distress 
thermometer and the Hospital Anxiety and 
Depression Scale, were removed in a protocol 
amendment two years after study activation due 
to considerations of patient burden, information 
redundancy and data management costs. The 
limited data collected are reported descriptively in 
Table A (supplementary appendix) given the 
scarcity of published PRO data in DCIS.(2) 
 
Outcomes 
The primary endpoint of the BIG 3-07/TROG 
07.01 study is time to local recurrence; this will be 
reported when participants have completed 5 
years of follow-up. Secondary endpoints are: 
overall survival; time to disease recurrence; 
cosmetic outcome; radiation toxicity; HRQL. The 
focus of this paper is HRQL at two years. All other 
secondary endpoints will be analysed and reported 
in subsequent papers. 
HRQL is a secondary endpoint. HRQL is a 
multi-dimensional construct, encompassing a 
broad range of impacts of diagnosis and treatment 
on patients’ perceptions, functioning and well-
being. To focus our hypotheses and reduce 
multiple-testing, our statistical analysis plan pre-
specified eight specific PROs: fatigue, physical 
functioning, cosmetic status, functional status, 
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breast-specific symptoms, body image and 
sexuality, perceived risk of invasive breast cancer 
(assessed in two ways, as described above). These 
PROs were selected because they are well-
established as key contributors to HRQL following 
treatment for early-stage invasive breast cancer.(1) 
We refer to these as ‘key PROs’. 
In addition to fatigue and physical 
functioning, the EORTC QLQ-C30 questionnaire 
assessed four other aspects of functioning (role, 
social, emotional, cognitive),  seven other 
symptoms (pain, dyspnoea, insomnia, loss of 
appetite, nausea/vomiting, diarrhoea, 
constipation), financial impact, and global HRQL. 
These were considered exploratory PROs.  
The clinical importance of PRO results from 
the EORTC QLQ-C30 (including fatigue and physical 
functioning) was determined used interpretation 
guidelines for differences between groups (11) and 
change over time (12). Since interpretation 
guidelines were not available for the other 
questionnaires, Cohen’s guidelines for effect sizes 
was used to interpret the observed mean 




The sample size for the HRQL substudy was 
calculated a priori for the primary PRO analysis, 
which aimed to detect a difference between the 
TBB and no TBB groups. To detect a difference of 
0.2 standard deviations of a PRO scale with 80% 
power at a two-sided alpha level of 5%, the 
required sample size was 790 patients. Allowing for 
a 5% annual attrition rate, the target sample size 
was 1020 patients. All patients recruited to the BIG 
3-07/TROG 07.01 study were eligible for the HRQL 
substudy, up to the HRQL target sample size, which 
was smaller than the total trial sample size.  
 The primary PRO hypothesis was that 
women randomised to receive TBB following WBRT 
will report: more fatigue and breast-specific 
symptoms; poorer perceived cosmetic outcome; 
poorer perception of body image and sexuality; 
and decreased perceived risk of invasive breast 
cancer; compared to women who do not receive 
TBB. The secondary hypothesis was that women 
who receive hypofractionated WBRT will report 
less fatigue and breast symptoms than those 
randomised to receive conventional WBRT but the 
groups will not differ in arm/shoulder-related 
functional status, cosmetic outcome, body image 
and sexuality, or perceived risk of invasive breast 
cancer.   
Analyses were conducted after the two-year 
HRQL data were mature due to the lack of 
randomised trials of DCIS reporting HRQL data and 
because systematic reviews of HRQL in DCIS and 
early stage invasive breast cancer indicate impact 
and recovery trajectories for relevant PROs 
stabilise by two years post-surgery (1, 2). Our  
primary PRO analysis compared TBB versus no TBB, 
with WBRT dose-fractionation included as a 
covariate. A secondary PRO analysis compared 
conventional versus hypofractionated WBRT, with 
TBB included as a covariate; limited to patients in 
randomisation category A only, plus a sensitivity 
analysis in all patients. Interactions between TBB 
and WBRT dose-fractionation were validly 
assessable only in the Category A patients.   
Responses to the questionnaires were 
scored into scales according to their respective 
standard scoring algorithms. If some items were 
missed, the scale score was imputed from the 
completed items if at least 50% of the items were 
completed. Otherwise the score was set to 
missing.(5) The proportion of patients who 
completed HRQL assessment at each scheduled 
time point was calculated, and the reasons and 
patterns of non-completion were examined via key 
PRO trajectories over time stratified by dropout 
time to assess whether missing data was likely to 
be missing completely at random or not.  
Each PRO (whether a key or exploratory 
PRO) was analysed as follows. For each PRO 
separately, participants with a score at baseline 
and at least one other time point were included. 
Generalised estimating equation (GEE) models 
were used to compare PRO scores by study arms, 
overall and at each assessment time point, 
adjusted for the respective baseline PRO levels and 
five pre-specified covariates [age (<50, ≥50 years), 
planned endocrine therapy (yes, no), geographic 
region (ANZS; Canada; the UK and Ireland; the rest 
of Western Europe), time since last surgery, 
number of ipsilateral breast surgical procedures] 
and three post-hoc covariates [tumour size 
(£20mm, >20mm), nodal surgery (axillary 
dissection or sentinel node biopsy, neither), upper 
outer tumour location (yes, no)]. Assessment time 
points were included categorically, and differences 
between study arms at each time point were 
estimated from GEE models.  
Adjustment for multiple hypothesis testing 
(14, 15) was confined to the 16 global tests (i.e. 8 
key PROs x 2 aspects of radiotherapy, TBB and 
WBRT dose-fractionation); each global test 
assessed the difference between treatment groups 
across all time points from the GEE model for 
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specific PRO and aspect of radiotherapy. As most 
correlations (Spearman’s) ranged 0.20-0.40, 
Hochberg adjustment methods were used.(16)  
The clinical importance of observed 
differences was assessed using interpretation 
guidelines for the QLQ-C30(11, 12) and Cohen’s 
effect sizes(13) for the other questionnaires.  
To complement the model estimates, 
trajectories of change from baseline were plotted 
for each PRO; these were based on the raw data, 
and were not adjusted for covariates. For 
completeness, descriptive statistics including 
sample size, mean and standard deviation for each 
PRO were tabulated at each assessment time point 
(Table B).  
To enable interpretation of the clinical 
importance of the six key PROs not derived from 
the EORTC QLQ-C30, effect size (ES) for the 
difference between TBB and no TBB at was 
calculated as the estimated difference between 
the groups divided by the standard deviation at 
baseline, with ES ³ 0.20 deemed clinically 
important (13).  
All analyses described above were pre-
specified in the statistical analysis plan,  approved 
by the Data and Safety Monitoring Committee 
October 23, 2015.  
The statistical analysis plan stated three 
additional hypotheses, but did not specify 
corresponding statistical analyses. The first two 
related to differences in baseline PROs by 
participating geographic region and randomisation 
category, respectively, with corresponding 
hypotheses: 1) Baseline PROs were similar 
between geographic region; 2) Baseline PROs were 
similar between the three randomisation 
categories. These two hypotheses were examined 
using Kruskal-Wallis tests, and are reported in this 
paper. The third hypothesis was: There will be 
good correlation (Spearman correlation coefficient 
> 0.7) between PRO scores relating to patients’ 
perceived cosmetic outcomes and EORTC cosmetic 
scores assessed by research staff of participating 
centres. Analyses regarding this hypothesis will be 
conducted for a future stand-alone paper. 
The following post-hoc analyses were 
conducted. Three additional covariates were added 
to GEE models (see above) and the models were 
re-estimated; results from the final models with 
eight covariates are reported. To determine 
whether SNB status was associated with PROs, we 
examined the PRO data at baseline and 2 years of 
the 988 patients who completed questionnaires at 
both time times. Correlations among the eight key 
PROs were be estimated to inform choice of critical 
p-value adjustment method. 
All statistical analyses were performed using 
SAS version 9.4, and all outcomes analyses were by 
intention-to-treat.  This study is registered with 
ClinicalTrials.gov, number NCT00470236. 
 
Role of the funding source 
The study funders had no role in study 
design, data collection, data analysis, data 
interpretation, or writing of this report. The 
corresponding author and senior author had full 
access to all study data and had final responsibility 
for the decision to submit for publication. 
 
Results 
Between June 1, 2007 and August 14, 2013, 
the trial recruited 1208 patients to the HRQL 
substudy from 118 hospitals in 11 countries. All 
these patients were followed up at two-years for 
this analysis. Figure 1 shows patient flow through 
to PRO analysis in Categories A, B and C. The 1147 
patients who completed measures at baseline and 
at least one other time point were included in 
analyses. Clinical and pathologic characteristics of 
the PRO analysis sample by allocation to TBB, and 
by fractionation schedule, are in Table 1, and by 
the four study arms in Tables C-D (Category A 
(n=377), all patients (n=1147)).   
Most patients completed scheduled HRQL 
assessments: 1147 (95%) of 1208 patients at 
baseline (1147), 988 (87%) of 1141 patients still on 
study at two years (Table 2, QLQ-C30; Table E for 
other PROs). At two years, reasons for missed 
questionnaires included site error (42/159=26%), 
patient did not attend clinic (28/159=18%), 
inconvenient for patient (11/159=7%), patient too 
busy (7/159=4%), patient not interested 
(6/159=4%). PRO trajectories over time stratified 
by dropout time (Figure B) show some poorer 
outcomes for the small number of patients who 
dropped out after EOT (n=25) and after 6 months 
(n=20), but not for those who dropped out after 12 
months (n=114). Post-hoc, we observed that the 
159 patients who did not complete QOL 
questionnaires at two years were more likely to 
have had sentinel node biopsy (SNB) than those 
who completed 2-year questionnaires, but 
otherwise were similar (Table F). This difference 
was unlikely to introduce bias because change 
from baseline to two years did not differ by SNB 
status (Table G, post-hoc analysis of the 988 
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patients who completed questionnaires at both 
time times). 
The impact of TBB was assessed in patients 
who completed PROs at baseline and at least one 
other time point (QLQ-C30, n=1147; BCTOS, n=920; 
BIS, n=919; CWS, n=908; Perceived Risk, n=878). 
Figure 2 presents the trajectory graphs for the 
eight key PROs. The largest differentials were 
observed in cosmetic and functional status (BCTOS-
CS, Fig 2c; BCTOS-FS, Fig 2d); these were the only 
PRO scales for which the global test was 
statistically significant after adjusting for multiple 
testing (BCTOS-CS estimate [95% confidence 
intervals] =0.10 [0.05, 0.15], p=0.00014, Hochberg-
adjusted p=0.0016; BCTOS-FS 0.08 [0.03, 0.13], 
p=0.0033, Hochberg-adjusted p=0.045). As Figure 
2c shows, cosmetic status worsened from baseline 
to EOT in both TBB and no TBB groups but more so 
in the TBB group (0.13 [0.06, 0.19], p=0.00020). 
Cosmetic improvement was observed in both 
groups over time after RT, but a marked 
differential due to TBB persisted at 12 months 
(0.10 [0.04, 0.17], p=0.0022) and 24 months (0.13 
[0.06, 0.20], p=0.00021). Figure 2d shows that arm 
and shoulder-related functional status also 
worsened from baseline to EOT in both groups, but 
more so in the TBB group (differences at EOT (0.08 
[0.01, 0.15], p=0.021), six months (0.11 [0.03, 
0.18], p=0.0045) and 12 months (0.09 [0.03, 0.16], 
p=0.0066)). Cosmetic and functional status of the 
no TBB group returned to baseline levels by 12 
months, but the TBB group reported persistent 
asymmetry at 24 months. Regarding the clinical 
importance of the BCTOS results, four between-
group differences (estimated from GEE models) 
achieved Cohen’s threshold for small but clinically 
important effect sizes (ES): arm/shoulder 
functional status at 6 months (ES=0.20) (Figure 2d); 
cosmetic status at EOT (ES=0.22) and 24 months 
(ES=0.22) (Figure 2c); breast-specific symptoms at 
EOT (ES=0.21) (Figure 2c). All other effect sizes for 
the BCTOS scales and time points ranged 0.13-
0.18, less than the 0.2 clinical importance 
threshold. 
None of the other six key PROs passed the 
global statistical significance test, with or  without 
Hochberg adjustments. Figures 2a, 2b and 2e-2h 
show their time trajectories. Estimated differences 
and effect sizes between TBB and no TBB at EOT 
for these six PROs were: fatigue 1.49 [-0.81, 3.80], 
p=0.20, ES=0.08; physical functioning -(-1.60 [-2.95, 
-0.24],p=0.021, ES=0.13; breast-specific symptoms 
0.15 [0.06, 0.25], p=0.002, ES=0.22; body 
image/sexuality 0.22 [-0.22, 0.66], p=0.33, ES=0.05; 
CWS -0.14 [-0.38, 0.10], p=0.24, ES=0.06; study-
specific question about perceived risk of invasive 
breast cancer -0.11 [-0.23, 0.01], p=0.07, ES=0.10.  
Of these, only breast-specific symptoms met the 
ES³0.20 threshold for clinical importance. 
Supplementary Figure C presents the 
trajectory graphs for the 13 exploratory PROs. Of 
these, only the EORTC QLQ-C30 role functioning 
scale had a global test p-value of less than 0.05 
(estimate -2.36 [95% CI -3.90, -0.81], p=0.0030; not 
included in Hochberg adjustment as it was not a 
key PRO). Figure Cb shows that role functioning 
deteriorated from baseline to EOT in both groups 
but more so in the TBB group (-3.41 [-6.02, -0.80], 
p=0.011). While there was improvement in both 
groups by six months, the differential in role 
functioning between the groups persisted at six 
months (-3.12 [-5.27, -0.96], p=0.0047) with the 
TBB group returning to baseline level and the no 
TBB group improving beyond baseline level. Social 
functioning followed a similar pattern (-2.91 [-5.17, 
-0.66], p=0.011 at EOT, -2.05 [-3.79, -0.32], p=0.020 
at six months; Figure Cc). However, none of these 
differences reached thresholds for clinical 
importance.(11)   
The impact of WBRT dose-fractionation was 
assessed among patients in randomisation 
category A who completed PROs at baseline and at 
least one other time point (QLQ-C30, n=377; 
BCTOS, n=376; BIS, n=377; CWS, n=373; Perceived 
Risk, n=359), and as a sensitivity analysis, among all 
patients (numbers per PRO questionnaire were as 
for the TBB analysis, given above).  None of the key 
PROs were statistically different in Hochberg-
adjusted global tests of dose-fractionation in 
Category A patients. The sensitivity analysis 
generally yielded similar model estimates. Figures 
3 and D show trajectory graphs for Category A and 
all patients, respectively. The only difference that 
was clinically important was for body image and 
sexuality at EOT among category A patients (-1.10 
[-1.79, -0.42], p=0.002, ES=0.25, Figure 3d), with 
those receiving hypofractionation reporting better 
body image/sexuality than those receiving 
conventional fractionation. None of the 
exploratory PROs were significantly different due 
to WBRT dose-fractionation, either in Arm A or all 
patients. 
There was a statistically significant 
interaction between TBB and WBRT dose-
fractionation for only one PRO scale, BCTOS-FS 
(p=0.0082), suggesting that the effect of the two 
parameters on arm and shoulder-related function 
was not simply additive. As Figure E shows, TBB  
had a detrimental effect on arm/shoulder function 
for patients who received conventional WBRT but 
not for those who received hypofractionated 
Quality of life after breast conserving therapy and adjuvant radiotherapy for non-low risk ductal carcinoma in situ (BIG 3-





WBRT . Those randomised to receive TBB following 
hypofractionated WBRT or no TBB after 
conventional WBRT experienced approximately the 
same degree of arm and shoulder function loss as 
those who were randomised to have no TBB after 
hypofractionated WBRT. 
There were some differences in PROs 
among geographic regions at baseline (Table I). 
Patients in Europe reported worse body image and 
sexuality than those in other regions (p<0.001);  
the largest difference was between Europe and 
ANZS (ES=0.60) and the smallest between Europe 
and UK/Ireland (ES=0.29). European patients had 
the worst perceived cosmetic status (p=0.008; 
BCTOS-CS ES=0.53). Cancer worry scores of 
patients in UK/Ireland  were somewhat higher than 
other regions (p=0.017; ES=0.27).  For the QLQ-
C30, even the largest differences were in the 
clinically small range:(11) role functioning 
(p<0.001, 9.0 points better in Canada than Europe); 
dyspnoea (p=0.0020, 5.2 points worse in Europe 
than the UK/Ireland); and financial problems  
(p<0.001, 6.5 points worse in ANZS than Europe).  
Results of the remaining two post-hoc 
analyses were as follows: 1) The inclusion three 
additional covariates post-hoc (tumour size, nodal 
surgery, upper outer tumour location) did not 
change results substantively. 2) Correlation 
between PRO scales ranged from 0.05 to 0.62 
(absolute values; Table H). The highest correlations 
were between fatigue and physical functioning 
(range 0.50-0.62 across assessment time points).  
The perceived risk of invasive breast cancer had 




Our study showed that TBB following breast 
conserving surgery and WBRT had a detrimental 
impact on patient-reported cosmetic outcomes, 
and arm and shoulder functional status. These 
impacts, evident by the end of RT, were sufficiently 
large to be clinically important.(11-13) The adverse 
effect of TBB on cosmetic status persisted at 24 
months whereas the effect on arm and shoulder 
functional status reached a clinically relevant 
threshold at 6 months and resolved by 24 months. 
The adverse impact of TBB on role, social and 
physical functioning did not reach thresholds for 
clinical importance and resolved by 24 months.  
TBB was not significantly associated with body 
image and sexuality or perceived risk of invasive 
breast cancer. Body image and sexuality were 
markedly worse at the end of treatment with 
conventional WBRT as compared to 
hypofractionated WBRT; this differential 
diminished somewhat with time. There was a 
cumulative adverse effect on arm and shoulder 
functional status for women who received both 
TBB and conventional WBRT. 
             In women with invasive breast cancer, 
WBRT is known to cause acute symptoms of 
fatigue,(17, 18) and breast-specific symptoms of 
radiation dermatitis, pain and oedema.(17-21) Our 
study confirmed these same outcomes in women 
with DCIS and provided useful evidence about the 
trajectories of their impact and recovery over time. 
The addition of TBB to WBRT did not have a 
significant impact on fatigue or social functioning, 
and was shown to have only a small, transitory 
impact on breast-specific symptoms. Previous trials 
of TBB irradiation in patients with invasive breast 
cancer reported limited data on acute toxicity and 
PROs but demonstrated a deleterious impact of 
TBB on physician reported cosmetic outcomes.(22) 
Our findings are important as they highlight the 
impact of TBB not only on patient-reported 
cosmetic outcomes but also functional outcomes 
and breast-specific symptoms. 
             The randomised Standardisation of Breast 
Radiotherapy (START) trials compared a number of 
hypofractionated WBRT schedules with 
conventional WBRT in patients with invasive breast 
cancer.(23) These trials demonstrated that the late 
radiation toxicities of breast shrinkage and 
telangiectasia that affected cosmetic outcome 
were less with hypofractionated WBRT (40 Gy in 15 
fractions over 3 weeks) compared to conventional 
WBRT (50 Gy in 25 fractions over 5 weeks). In the 
2208 women who participated in their PRO study, 
the only PRO that differed significantly at 5 years 
was a change in skin appearance. Adverse change 
in skin appearance was significantly less for women 
who received 39 Gy in 13 fractions over 5 weeks or 
40 Gy in 15 fractions over 3 weeks compared to 
those who received 50 Gy in 25 fractions.(24) 
Consistent with our findings, the START trials 
showed no evidence that hypofractionated WBRT 
was associated with significant differences in any 
other breast, arm or shoulder symptoms or body 
image.   
In another randomised trial (n=287; 22% 
DCIS, 78% early breast cancer), patients allocated 
to hypofractionated WBRT reported less fatigue at 
6 months after RT than those assigned 
conventional WBRT when TBB was used in both 
trial arms.(25) There were no differences between 
trial arms at 6 months or 3 years in any of the 
BCTOS scales or in body image.(26)  
Quality of life after breast conserving therapy and adjuvant radiotherapy for non-low risk ductal carcinoma in situ (BIG 3-





While our study showed that TBB 
adversely impacted perceived cosmetic status, it 
did not confirm the expected adverse consequence 
on body image and sexuality.(27) While the latter 
finding is consistent with evidence that women 
treated for DCIS experience little impact on body 
image,(2) the lack of association between 
perceived cosmetic status and body image 
contrasts with other studies where they were 
correlated.(28, 29) The lack of impact on body 
image and sexuality in our study might be related 
to psychological adaptation, or the impact on 
perceived cosmetic status being confined to only 
part of the breast while the impact on body image 
and sexuality was previously evaluated across 
interventions that affected the whole breast.   
The reasons that TBB was associated with 
adverse arm and shoulder function after 
conventional WBRT were unclear. Nodal surgery is 
known to affect the issues covered by the BCTOS-
FS items in invasive breast cancer (1) but inclusion 
of nodal surgery as a covariate in our post-hoc 
analysis did not change results substantively. The 
use of high tangents for WBRT could affect arm 
and shoulder symptoms but was unlikely to be 
used in patients with DCIS and differential use by 
TBB could not be evaluated as it was not recorded 
in the study database. TBB location differences 
between the boost or fractionation groups is 
unlikely to account for the finding as there were 
only small differences in the percentages of upper 
outer quadrant tumour locations.  WBRT 
fractionation did not affect BCTOS-FS scores in 
Category A patients so it seems unlikely that the 
worse arm and shoulder function was a direct 
result of the use of conventional WBRT. However, 
some patients develop shoulder problems due to 
the mechanics of lifting the arms over the head to 
accommodate tangent and boost RT in the supine 
position, and one could speculate that the 
increased number of treatment visits and 
requirements for daily shoulder abduction 
(25+8=33 over 6.5 weeks vs. 16+8=24 over 5 
weeks) might have had some effect of shoulder 
discomfort, but that this should have been 
transient and have resolved by 2 years. It is more 
the observation was a chance finding despite the 
use of randomisation, the large sample size, and 
adjustment for multiple hypothesis testing in this 
study. 
Our findings did not support our 
hypothesis that women randomised to receive TBB 
would have a lower perceived risk of invasive 
breast cancer. Other studies found that women 
diagnosed with DCIS had exaggerated fears of 
breast cancer recurrence and dying of breast 
cancer, which occurred early and persisted for 
many years.(2) In contrast, participants of our 
study expressed concerns about getting invasive 
breast cancer at baseline but these subsided 
steadily and by 24 months, had been reduced by a 
small but clinically relevant extent (0.3 effect size).  
Our study adds to knowledge about 
recovery trajectories in women diagnosed and 
treated for DCIS. The results were consistent with 
published studies that core aspects of HRQL were 
initially impacted but most returned to baseline 
within 24 months.(2) The degree of worsening 
across the core aspects of HRQL was generally 
small except for fatigue scores, which showed a 
substantial deterioration at EOT. Emotional 
function measured using QLQ-C30 was not 
adversely impacted during RT.   
While several baseline PROs were 
statistically different between geographic regions 
(P<0.05), these were generally small and there was 
not a consistent pattern for one region being 
worse across domains. Since multiple comparisons 
were conducted, false positive findings were 
possible. Any true differences might be attributed 
to differences in health care practices, cultural 
attitudes or linguistic nuances in translation of 
PROs instruments.  
To our knowledge, this is the first 
prospective PROs study conducted in a large, well-
defined, homogeneously treated cohort of women 
with pure DCIS of the breast in an international 
randomised trial examining the effects of TBB and 
WBRT dose-fractionation schedules. Study 
participants were longitudinally assessed at pre-
defined intervals over two years using reliable and 
valid instruments, PRO completion rates were high 
(87% at 2 years), and the reasons and patterns of 
non-completion suggested the missing data were 
generally missing completely at random, giving us 
confidence in the robustness of the findings.   
Another study strength was that only 14% 
of the PRO study participants received adjuvant 
endocrine therapy so the reported-patient 
experiences were primarily a measure of the 
impact of their diagnosis and local therapies 
without the confounding effect of endocrine 
therapy-related toxicity. The physical effects of 
WBRT with or without TBB are expected to be the 
same for women with early-stage invasive breast 
cancer and women with DCIS. Therefore, the 
magnitude of the impacts of local therapy 
observed in our study could reasonably be 
extrapolated to patients with early-stage invasive 
breast cancer, and serve as a baseline for 
distinguishing the impact of local therapy from that 
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of systemic therapy during the first two years after 
diagnosis. 
Our study had some limitations arising 
from a study design feature included to enhance 
feasibility of enrolment: each centre elected to 
participate in one of three randomisation 
categories. Only Category A involved 
randomisation between TBB vs no TBB and 
conventional WBRT vs hypofractionated WBRT, 
which enabled assessment of interactions between 
TBB and WBRT dose-fractionation, and minimised 
systematic bias due to institutional factors. 
However, this restricted sample size; a post-hoc 
power calculation determined that the 377 
Category A patients provided 80% power at a two-
sided alpha level of 5% to detect a difference 
between the two WBRT fractionation arms of 0.3 
standard deviations, which is considered clinically 
significant(11).  The sensitivity analyses (including 
patients from all randomisation categories) had a 
greater sample size but the potential for 
confounding of results by systematic differences in 
centres that selected conventional WBRT or 
hypofractionated WBRT.  Local convention likely 
accounted for institutional variations in the use of 
conventional or hypofractionated WBRT, but 
participating clinician biases, health care system 
factors, and factors underlying regional difference 
in PRO may all have contributed towards 
variations. All statistical models included several 
covariates (age, planned endocrine therapy, time 
since last surgery, number of ipsilateral breast 
surgical procedures,tumour size, upper-outer 
tumour location, nodal surgery and geographic 
region) to adjust for any systematic differences 
between institutions regarding these variables in 
the sensitivity analyses. 
There were several challenges common to 
PRO studies. Maintaining a pre-determined Type I 
error level is difficult when outcomes are 
correlated, and adjustments to control Type I error 
inflation could reduce power in detecting 
significant differences. Simple Bonferroni 
adjustment assumes that outcomes are 
independent, so is overly conservative when 
outcomes are correlated (i.e. the actual Type 1 
error rate is more restrictive than intended). As the 
correlations in our dataset were between 0.20 and 
0.40, we elected to apply the Hochberg method, as 
this maximizes power while controlling Type I error 
when correlations were in this range.(16) To avoid 
being overly restrictive, we confined adjustment 
for multiple hypothesis testing to 16 global tests 
including 8 key PROs and 2 sets of global 
hypotheses (TBB, WBRT dose-fractionation). In 
addition, PRO results must be interpreted in the 
context of clinical importance in addition to 
statistical significance.(14, 15) We achieved this by 
using available interpretation guidelines for the 
QLQ-C30, and well-established effect size 
thresholds for other PROs measures. 
In conclusion, this prospective evaluation of 
PROs from baseline to two years in a large, 
international randomised trial of radiation doses 
and fractionation schedules following breast 
conserving surgery in women with DCIS showed a 
modest but persistent adverse impact of TBB on 
cosmetic and functional status while the impact on 
HRQL was small and transient. There was evidence 
to support that hypofractionated WBRT was better 
tolerated by patients than conventional WBRT. 
Longer term follow up will need to confirm the 
trends observed in HRQL at 2 years.  In the interim, 
published studies evaluating the efficacy of TBB for 
DCIS in reducing the risks of local recurrence and 
salvage mastectomy rates are limited to 
retrospective analyses, which yielded conflicting 
results.(30) Until the efficacy results of BIG 3-
07/TROG 07.01 are published, the PROs data serve 
to inform shared treatment decision-making in 
weighing the potential benefits against the adverse 
effects of TBB and WBRT fractionation schedules in 
the context of individualised recurrence risk 
assessment and patient preferences.  
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Table 1: Patient characteristics at baseline for patients included in analysis: boost vs no boost (n=1147); conventional vs hypofractionated 
WBRT (n=347, randomization Category A only and n=1147*, all patients) 
 
 Tumour bed boost 
WBRT dose-fractionation 
(Category A) 















Age <50 102 (18%) 105 (18%) 37 (20%) 36 (19%) 120 (20%) 87 (16%) 
 
 
≥50 472 (82%) 468 (82%) 151 (80%) 153 (81%) 495 (80%) 445 (84%) 
Region Australia, New Zealand, Singapore 212 (37%) 215 (38%) 134 (71%) 134 (71%) 285 (46%) 142 (27%) 
 Canada 117 (20%) 116 (20%) 17 (9%) 13 (7%) 51 (8%) 182 (34%) 
 United Kingdom, Ireland 110 (19%) 110 (19%) 32 (17%) 37 (20%) 90 (15%) 130 (24%) 
 
 
Europe 135 (24%) 132 (23%) 5 (3%) 5 (3%) 189 (31%) 78 (15%) 
Tumour location Upper outer quadrant 201 (35%) 219 (38%) 71 (38%) 70 (37%) 224 (36%) 196 (37%) 
 Upper inner quadrant 60 (10%) 52 (9%) 22 (12%) 17 (9%) 57 (9%) 55 (10%) 
 3 o’clock 32 (6%) 45 (8%) 13 (7%) 7 (4%) 43 (7%) 34 (6%) 
 12 o’clock 50 (9%) 39 (7%) 14 (7%) 23 (12%) 46 (7%) 43 (8%) 
 Central (within 3cm radius of 
nipple) 
65 (11%) 91 (16%) 18 (10%) 20 (11%) 90 (15%) 66 (12%) 
 Lower inner quadrant 35 (6%) 32 (6%) 13 (7%) 11 (6%) 30 (5%) 37 (7%) 
 Lower outer quadrant 62 (11%) 38 (7%) 13 (7%) 18 (10%) 57 (9%) 43 (8%) 
 6 o’clock 27 (5%) 24 (4%) 9 (5%) 10 (5%) 23 (4%) 28 (5%) 
 9 o’clock 
 
41 (7%) 33 (6%) 15 (8%) 13 (7%) 44 (7%) 30 (6%) 
Number of re-excisions following initial surgery 0 395 (69%) 382 (67%) 122 (65%) 112 (59%) 414 (67%) 363 (68%) 
 1 166 (29%) 170 (30%) 58 (31%) 73 (39%) 177 (29%) 159 (30%) 
 2 7 (1%) 16 (3%) 6 (3%) 2 (1%) 16 (3%) 7 (1%) 
 3 3 (1%) 0 (0%) 0 (0%) 1 (1%) 1 (0%) 2 (0%) 
 At least 1 3 (1%) 4 (1%) 1 (1%) 1 (1%) 6 (1%) 1 (0%) 
 Unknown 0 (0%) 1 (0%) 1 (1%) 0 (0%) 1 (0%) 0 (0%) 
        
Sentinel Node Biopsy Yes 127 (22%) 121 (21%) 37 (20%) 39 (21%) 146 (24%) 102 (19%) 
 No 447 (78%) 452 (79%) 151 (80%) 150 (79%) 469 (76%) 430 (81%) 
 
 Tumour bed boost 
WBRT dose-fractionation 
(Category A) 















Axillary Dissection Yes 8 (1%) 13 (2%) 0 (0%) 1 (1%) 12 (2%) 9 (2%) 
 No 
 
566 (99%) 560 (98%) 188 (100%) 188 (99%) 603 (98%) 523 (98%) 
Microscopic tumour size Less than or equal to 20mm 358 (62%) 368 (64%) 115 (61%) 117 (62%) 371 (60%) 355 (67%) 
 21mm to 50mm 172 (30%) 165 (29%) 55 (29%) 63 (33%) 194 (32%) 143 (27%) 
 Greater than 50mm 25 (4%) 24 (4%) 16 (9%) 8 (4%) 29 (5%) 20 (4%) 
 Unknown 
 
19 (3%) 16 (3%) 2 (1%) 1 (1%) 21 (3%) 14 (3%) 
Months from surgery to randomization Mean (s.d.) 1.4 (0.9) 1.4 (0.6) 1.5 (0.6) 1.5 (0.6) 1.4 (0.5) 1.5 (1.0) 
 Min , Max 0.3 , 3.0 0.3 , 3.0 0.3 , 2.9 0.3 , 2.8 0.3 , 2.9 0.3 , 3.0 
 Median (Q1 , Q3) 1.4 (1.0 , 1.8) 1.4 (1.0 , 1.8) 1.4 (1.1 , 1.9) 1.4 (1.0 , 1.8) 1.3 (1.0 , 1.7) 1.5 (1.1 , 1.9) 
 
Planned endocrine therapy Yes 78 (14%) 82 (14%) 17 (9%) 19 (10%) 49 (8%) 111 (21%) 
 
 
No 496 (86%) 491 (86%) 171 (91%) 170 (90%) 566 (92%) 421 9%) 
Menopausal status Premenopausal 156 (27%) 166 (29%) 53 (28%) 57 (30%) 175 (28%) 147 (28%) 
 Postmenopausal 416 (72%) 406 (71%) 135 (72%) 130 (69%) 440 (72%) 382 (72%) 
 Unknown 2 (0%) 1 (0%) 0 (0%) 2 (1%) 0 (0%) 3 (1%) 
        
Initial tumour presentation Non-palpable lesion 481 (84%) 480 (84%) 164 (87%) 165 (87%) 504 (82%) 457 (86%) 
 Palpable lesion 55 (10%) 55 (10%) 19 (10%) 18 (10%) 61 (10%) 49 (9%) 
 Unknown 38 (7%) 38 (7%) 5 (3%) 6 (3%) 50 (8%) 26 (5%) 
        
Laterality of breast tumour Left 285 (50%) 299 (52%) 87 (46%) 97 (51%) 307 (50%) 277 (52%) 
 Right 289 (50%) 274 (48%) 101 (54%) 92 (49%) 308 (50%) 255 (48%) 
 *These 1147 patients completed measures at baseline and at least one other time point. 
  
Table 2: Compliance with the planned PRO assessment schedule for the EORTC QLQ-C30 for n=1208 patients recruited to the quality of life 
substudy of the BIG 3-07 trial (all sites, 1 June 2007 – 14 August 2013) 
HRQOL data 
collection time-point 
Number of patients recruited to 
HRQOL study and still on studyc (N) 
at HRQOL data collection time-point 
Compliancea with planned 
HRQOL questionnaires (n) 
Percentage of patients still on study 
with missing HRQOL data  
No boost Boost Total No boost Boost Total No boost (%) Boost (%) Total (%) 
Baseline   605 603 1207b 574 573 1147 5.0 % 5.0 % 5.0 % 
End of RT 598 590 1188 550 541 1091 8.0 % 8.3 % 8.2 % 
6 months post RT 583 571 1154 507 512 1019 13 % 10 % 12 % 
12 months post RT 582 572 1154 523 523 1046 10 % 8.6 % 9.4 % 
24 months post RT 569 572 1141 492 496 988 14 % 13 % 13 % 
a. Compliance with the planned PRO assessment schedule was calculated for each PRO data collection time point as the proportion of patients still on study at that time 
point. 
b. One patient of the 1208 withdrew from HRQOL study prior to baseline as she did not speak English. 
c. On study indicates the patient had not: died, withdrawn consent for further involvement in the study, or been reported as lost to follow up by the site. 
 
 
On study indicates the patient had not: died, withdrawn consent for further involvement in the study, or been reported as lost to follow up by the site. 
Compliant at 24 months indicates that the patient submitted planned HRQOL questionnaires at the 24 month timepoint. “Did not receive allocated intervention” was determined as site not reporting treatment with allocated total dose and fractions for both 
boost or no boost and fractionation schedule. 
 









Allocated to intervention 
Received allocated intervention 
(Did not receive allocated intervention)   
 
 
On study at 24 months 
(Lost to follow up) 
 
 
Analysed in PROs substudy 
(Did not submit required PROs data)  
Compliant at 24 months
n = 94 
(n = 4) 
n = 84 
 
n = 95 
(n = 3) 
 




 n = 98 
n = 95 
(n = 3) 
 
 
 n = 96 
(n = 4) 
 




 n = 100 
n = 93 
(n = 7) 
n = 93 
(n = 7) 







Category A (n = 396) 
Enrollment 




 n = 100 
n = 90 
(n = 10)  
 n = 94 
(n = 6) 
 




 n = 98 
n = 88 
(n = 10) 
 n = 93 
(n = 5) 
 
n = 94 
(n = 6) 




n = 96 
(n = 2) 








n = 183 
n = 159 
(n = 24) 
 
n = 173 
(n = 10) 
 




 n = 182 
 n = 157 
 (n = 25) 
n = 176 
(n = 6) 
 
n = 175 
(n = 8) 




n = 168 
(n = 14) 





Category C (n = 365) 
 
n = 212 
(n = 12) 
n = 172 
 
 
 n = 205 
(n = 19) 
 




 n = 224 
 n = 217 
 (n = 7) 
 
 
n = 209 
(n = 14) 
 




 n = 223 
 n = 199 
 (n = 24)  
 
n = 215 
(n = 8) 




Category B (n = 447) 
 
Total recruited to HRQOL substudy 1 June 2007 to 14 August (n = 1208)  
 
On study indicates the patient had not: died, withdrawn consent for further involvement in the study, or been reported as lost to follow up 
by the site. 
Compliant at 24 months indicates that the patient submitted planned HRQOL questionnaires at the 24 month timepoint. “Did not receive 
allocated intervention” was determined as site not reporting treatment with allocated total dose and fractions for both boost or no boost 
and fractionation schedule. 
 
Figure 2. Mean changes from baseline (with 95% confidence intervals) by tumour bed boost for the pre-specified key PROs. 
 
2a) EORTC QLQ-C30 Fatigue (higher is worse) 2b) EORTC QLQ-C30 Physical functioning (higher is better) 
  
2c) BCTOS Cosmetic Status (higher is worse) 2d) BCTOS Arm and Shoulder Functional Status (higher is worse) 
  
2e) BCTOS Breast Symptoms (higher is worse) 
 
2f) Body Image Scale (BIS) (higher is worse) 
 
 
2g) Cancer Worry Scale (CWS) (higher is worse) 
 
2h) Perceived risk of invasive breast cancer (higher is worse) 
 
EORTC QLQ-C30 scales range from 0-100. Body Image Scale (BIS) ranges from 0-30. Cancer Worry Scale (CWS) ranges 0-16. 
Breast Cancer Treatment Outcome Scale (BCTOS): All scales range 1-4, higher score indicates more asymmetry between treated and 
untreated side. Cosmetic status issues include: breast size, texture, shape and elevation, nipple appearance, scar tissue, and fit of bra 
and clothing. Functional status issues include: arm and shoulder movement, stiffness and pain and ability to lift objects. Breast-specific 
symptoms include breast pain, tenderness and sensitivity. 
Perceived risk of invasive breast cancer:  “In your opinion, compared with other women your age who have had DCIS, what are your 
chances of getting invasive breast cancer?”, five response options: much lower (1); somewhat lower (2); the same (3); somewhat higher 
(4); a lot higher (5). 
These plots represent mean changes and 95% confidence intervals calculated from the raw data; they are not model estimates, and they 
are not adjusted for any covariates. 
  
On study indicates the patient had not: died, withdrawn consent for further involvement in the study, or been reported as lost to follow up 
by the site. 
Compliant at 24 months indicates that the patient submitted planned HRQOL questionnaires at the 24 month timepoint. “Did not receive 
allocated intervention” was determined as site not reporting treatment with allocated total dose and fractions for both boost or no boost 
and fractionation schedule. 
 
Figure 3. Mean of changes from baseline (with 95% confidence intervals) by radiation dose fractionation (Category A patients only) for the pre-
specified key PROs. 
 
3a) QLQ-C30 Fatigue (higher is worse) 3b) QLQ-C30 Physical functioning (higher is better) 
 
 
3c) BCTOS Cosmetic Status (higher is worse)  3d) BCTOS Functional Status (higher is worse) 
  
3e) BCTOS Breast Symptoms (higher is worse) 
 
 
3f) Body Image Scale (BIS) (higher is worse) 
 
 
3g) Cancer Worry Scale (CWS) (higher is worse) 
 
3h) Perceived risk of invasive breast cancer (higher is worse) 
 
EORTC QLQ-C30 scales range from 0-100. Body Image Scale (BIS) ranges from 0-30. Cancer Worry Scale (CWS) ranges 0-16. 
Breast Cancer Treatment Outcome Scale (BCTOS): All scales range 1-4, higher score indicates more asymmetry between treated and 
untreated side. Cosmetic status issues include: breast size, texture, shape and elevation, nipple appearance, scar tissue, and fit of bra 
and clothing. Functional status issues include: arm and shoulder movement, stiffness and pain and ability to lift objects. Breast-specific 
symptoms include breast pain, tenderness and sensitivity. 
Perceived risk of invasive breast cancer:  “In your opinion, compared with other women your age who have had DCIS, what are your 
chances of getting invasive breast cancer?”, five response options: much lower (1); somewhat lower (2); the same (3); somewhat higher 
(4); a lot higher (5). 
These plots represent mean changes and 95% confidence intervals calculated from the raw data; they are not model estimates, and they 
are not adjusted for any covariates. 
 
 
Quality of life after breast conserving therapy and adjuvant radiotherapy for non-low risk 
ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised controlled 
trial   
Madeleine T. King, Emma K. Link, Tim Whelan, Ivo A. Olivotto, Ian Kunkler, A. Helen Westenberg, 




Table of contents Pages 
Figure A. Randomisation categories 1 
Figure B. Missing data patterns for key PROs: trajectories of mean PRO scores stratified 
by dropout time 
2-3 
Figure C. Mean changes from baseline (with 95% confidence intervals) by tumour bed 
boost for the exploratory PROs 
4-7 
Figure D. Mean of changes from baseline by radiation dose fractionation among all 
patients for the pre-specified key PROs 
8-9 
Figure E. Mean of changes from baseline in arm and shoulder-related functional status 
(BCTOS-FS) with 95% CI by randomised arm (positive change indicates worsening), 
Category A patients only (n=377) 
10 
Table A. Hospital anxiety and depression scale and distress summaries over time by 
tumour bed boost 
11 
Table B. Patient-reported outcome summaries over time by tumour bed boost 12-14 
Table C. Patient characteristics at baseline for patients included in PRO analysis by 
Treatment Arm, randomisation category A only (n=377). 
15-16 
Table D. Patient characteristics at baseline for patients included in analysis by treatment 
arm (n=1147) 
17-18 
Table E. Patient-reported outcome (PRO) compliance and missing data rates for patients 
recruited at non-EORTC sitesa for Breast Cancer Treatment Outcome Scale (BCTOS), Body 
Image Scale (BIS), Cancer Worry Scale (CWS); (n=968 patients recruited to the BIG 3-07 
trial at non-EORTC sites June 2007 – 14 August 2013) 
19 
Table F. Patient characteristics at baseline for patients included in analysis: boost vs no 
boost (n=1147), by those with and without 2 year visit quality of life data 
20-21 
Table G. Patient-reported outcome (PRO) scores a1t baseline and two years, by sentinel 
node biopsy at baseline, for patients who completed PRO questionnaires are baseline 
and two years (n=988) 
22 
Table H.  Correlations among 8 key patient-reported outcomes (PROs) at each PRO 
assessment timepoint (Spearman’s rank correlation coefficient) 
23-24 
Table I. Patient-reported outcome summaries at baseline by geographic region 25 
List of BIG 3-07/TROG 07.01 principal investigators and sites which recruited patients to 





















Whole breast radio- 
therapy (WBRT) 
No tumour bed boost 
WBRT 





Conventionally fractionated WBRT 
50 Gy/25 fractions/35 days 
Hypofractionated WBRT 
42.5 Gy/16 fractions/22 days 
Conventionally fractionated WBRT 
50 Gy/25 fractions/35 days 
Boost 16 Gy/8 fractions/10 days 
Hypofractionated WBRT 
42.5 Gy/16 fractions/22 days 












No tumour bed boost 
WBRT 
plus tumour bed boost 
Arm 1 
Arm 3 
Conventionally fractionated WBRT 
50 Gy/25 fractions/35 days 
 
Conventionally fractionated WBRT 
50 Gy/25 fractions/35 days 












No tumour bed boost 
WBRT 




42.5 Gy/16 fractions/22 days 
 
Hypofractionated WBRT 
42.5 Gy/16 fractions/22 days 
Boost 16 Gy/8 fractions/10 days 
 
Category A 
Category B (Conventionally fractionated WBRT) 





Figure B Missing data patterns for key PROs: trajectories of mean scores over time stratified by dropout time 
 
a)  EORTC QLQ-C30 Physical functioning (scale range: 0-100, higher is better) b)  EORTC QLQ-C30 Fatigue (scale range: 0-100, higher is worse) 
  
 








Figure B: (cont.) Missing data patterns for key PROs: trajectories of mean scores over time stratified by dropout time 
 
e)  BCTOS breast-specific symptoms (scale range: 1-4, higher is worse)  f)  Body image scale (scale range: 0-30, higher is worse) 
  
 







Figure C. Mean changes from baseline* (with 95% confidence intervals) by tumour bed boost for the exploratory PROs. 
 
a)  EORTC QLQ-C30 Global HRQL (higher is better) 
 
b)  EORTC QLQ-C30 Role functioning (higher is better) 
 
c)  EORTC QLQ-C30 Social functioning (higher is better) 
 
d)  EORTC QLQ-C30 Emotional functioning (higher is better) 
 






Figure C: (cont.) Mean changes from baseline* (with 95% confidence intervals) by tumour bed boost for the exploratory PROs. 
 
e)  EORTC QLQ-C30 Cognitive (higher is better) 
 
f)  EORTC QLQ-C30 Financial impact (higher is worse)   
 
g) EORTC QLQ-C30 Pain (higher is worse)   
 
h) EORTC QLQ-C30 Dyspnoea (higher is worse)   
 
All EORTC QLQ-C30 scales range from 0-100. 





Figure C: (cont.) Mean changes from baseline* (with 95% confidence intervals) by tumour bed boost for the exploratory PROs. 
 
i) EORTC QLQ-C30 Insomnia (higher is worse)   
 
j) EORTC QLQ-C30 Loss of appetite (higher is worse)  
 
k) EORTC QLQ-C30 Nausea/vomiting (higher is worse)     
 
l) EORTC QLQ-C30 Diarrhoea (higher is worse)    
 
 





Figure C: (cont.) Mean changes from baseline* (with 95% confidence intervals) by tumour bed boost for the exploratory PROs. 
 
m) EORTC QLQ-C30 Constipation (higher is worse)   
 
* Change from baseline calculated as follow-up value minus baseline value 
 
8 
Figure D. Mean of changes from baseline* by radiation dose fractionation among all patients, for the pre-specified key PROs. 
a) EORTC QLQ-C30 Fatigue (higher is worse) b) EORTC QLQ-C30 Physical functioning (higher is better)
c) BCTOS Cosmetic Status (higher is worse)
* Change from baseline calculated as follow-up value minus baseline value
d) BCTOS Functional Status (higher is worse)
9 
e) BCTOS Breast Symptoms (higher is worse) f) Body Image Scale (BIS) (higher is worse)
g) Cancer Worry Scale (CWS) (higher is worse) h) Perceived risk of invasive breast cancer (higher is worse)
EORTC QLQ-C30 scales range from 0-100. Body Image Scale (BIS) ranges from 0-30. Cancer Worry Scale (CWS) ranges 0-16. 
Breast Cancer Treatment Outcome Scale (BCTOS): All scales range 1-4, higher score indicates more asymmetry between treated and untreated side. Cosmetic status 
issues include: breast size, texture, shape and elevation, nipple appearance, scar tissue, and fit of bra and clothing. Functional status issues include: arm and shoulder 
movement, stiffness and pain and ability to lift objects. Breast-specific symptoms include breast pain, tenderness and sensitivity. 
Perceived risk of invasive breast cancer:  “In your opinion, compared with other women your age who have had DCIS, what are your chances of getting invasive breast 
cancer?”, five response options: much lower (1); somewhat lower (2); the same (3); somewhat higher (4); a lot higher (5). 
These plots represent mean changes (calculated as follow-up value minus baseline value) and 95% confidence intervals calculated from the raw data; they are not model 
estimates, and they are not adjusted for any covariates. 
10 
Figure E. Mean of changes from baseline in arm and shoulder-related functional status (BCTOS-FS) with 95% CI by 
randomised arm (positive change indicates worsening), Category A patients only: Arm 1 [conventionally fractionated whole 
breast radiotherapy (WBRT) only], Arm 2 [hypofractionated WBRT only], Arm 3 [conventionally fractionated WBRT + tumour 
bed boost (TBB)], Arm 4 [hypofractionated WBRT +TBB] 
11 
 
Supplementary Table A. Hospital anxiety and depression scale and distress summaries over time by tumour bed boost 
A higher scale indicates more anxiety/depression or distress. 
 






















Hospital anxiety scale (0-21) N 88 86 57 41 10 86 82 54 38 13 
 Mean (s.d.) 8.17 (1.16) 8.28 (1.83) 8.16 (1.42) 8.37 (1.11) 7.90 (1.37) 8.02 (1.61) 7.80 (1.20) 7.89 (1.27) 7.97 (1.33) 8.62 (1.45) 
            
Hospital depression scale (0-21) N 87 87 57 41 10 84 82 54 38 13 
 Mean (s.d.) 12.46 (2.41) 12.28 (2.64) 12.39 (2.80) 12.78 (2.57) 12.90 (2.92) 12.60 (2.30) 12.96 (1.82) 12.46 (2.40) 12.47 (2.60) 12.77 (2.42) 
            
Distress thermometer (0-10) N 84 83 54 39 10 83 80 49 38 12 





Supplementary Table B. Patient-reported outcome summaries over time by tumour bed boost 
Tabulated form of figures:  sample size, mean and standard deviation for each PROs at each assessment time point, e.g. for future use in meta-analyses. 
EORTC QLQ-C30: A high score for the global health status/QoL and functional scales represent a high/healthy level of functions, but a high score for a symptom scale/item represents a high level of 
symptomatology/problems. 
BCTOS: A higher score indicates greater perceived difference between the treated and untreated breast and area. 
BIS: A higher score represents more symptoms/distress. 
CWS: A higher cancer worry scale indicates more cancer worries. 
Perceived risk:  In your opinion, compared with other women your age who have DCIS, what are your chances of getting invasive breast cancer? 
 






















EORTC QLQ-C30            
Global health status/QoL N 573 547 505 521 487 573 539 509 518 489 
 Mean (s.d.) 78.1 (17.3) 72.8 (19.4) 78.2 (18.0) 78.9 (18.3) 77.8 (20.1) 78.6 (17.4) 72.0 (18.8) 77.6 (18.3) 78.4 (17.9) 79.9 (17.8) 
            
Physical functioning N 574 546 506 523 491 573 541 510 521 495 
 Mean (s.d.) 91.8 (11.2) 88.3 (13.6) 90.9 (12.1) 91.4 (12.8) 90.5 (13.5) 91.5 (12.9) 86.6 (15.3) 89.6 (14.6) 91.0 (13.3) 91.1 (13.7) 
            
Role functioning N 573 547 506 523 490 573 539 510 523 496 
 Mean (s.d.) 88.3 (19.0) 80.3 (23.3) 91.9 (16.3) 92.1 (16.3) 91.4 (19.0) 87.5 (20.2) 76.6 (24.8) 88.1 (20.7) 90.1 (19.8) 90.7 (19.6) 
            
Emotional functioning N 573 550 506 520 490 573 540 510 520 492 
 Mean (s.d.) 79.0 (19.5) 79.2 (20.6) 82.2 (19.6) 83.2 (19.3) 83.5 (19.0) 79.2 (18.9) 79.8 (19.3) 81.1 (19.0) 83.1 (19.7) 84.3 (18.7) 
            
Cognitive functioning N 573 550 506 521 490 573 540 511 520 492 
 Mean (s.d.) 87.6 (17.2) 83.1 (20.3) 86.6 (17.6) 87.0 (18.0) 86.9 (18.1) 88.0 (17.5) 83.0 (20.5) 85.8 (17.6) 86.4 (17.6) 87.2 (18.6) 
            
Social functioning N 572 550 505 521 490 572 539 510 520 492 
 Mean (s.d.) 90.1 (17.2) 84.7 (20.5) 94.3 (13.1) 93.8 (15.5) 92.9 (18.1) 89.4 (17.1) 81.4 (22.2) 91.4 (16.8) 93.0 (15.4) 93.0 (16.9) 
            
Fatigue N 573 546 505 523 491 573 541 510 523 495 
 Mean (s.d.) 19.0 (18.2) 32.7 (23.0) 19.1 (18.8) 17.9 (19.0) 18.5 (20.6) 19.6 (19.0) 34.7 (22.1) 21.5 (20.6) 19.5 (19.7) 18.2 (19.9) 
            
Nausea/vomiting N 573 548 506 523 491 573 541 512 523 496 
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 Mean (s.d.) 2.3 (8.2) 6.2 (12.7) 3.0 (9.1) 3.0 (9.2) 3.0 (9.5) 2.5 (8.1) 6.7 (12.6) 3.3 (9.4) 3.1 (10.4) 2.8 (10.4) 
            
Pain N 574 550 507 523 492 573 541 512 523 496 
 Mean (s.d.) 14.6 (18.4) 19.8 (20.3) 16.8 (20.2) 12.8 (19.7) 14.1 (21.8) 14.3 (19.4) 22.9 (22.5) 17.2 (21.1) 13.2 (19.2) 13.0 (19.9) 
            
Dyspnoea N 572 545 503 522 489 571 541 511 523 496 
 Mean (s.d.) 7.5 (16.8) 12.5 (21.2) 10.9 (19.1) 10.0 (18.6) 11.9 (20.8) 6.9 (16.5) 12.0 (20.4) 10.8 (20.5) 10.8 (20.4) 10.9 (21.2) 
            
Insomnia N 571 547 505 523 491 573 539 510 523 495 
 Mean (s.d.) 28.1 (28.9) 28.6 (29.3) 24.2 (27.9) 23.5 (28.1) 23.7 (29.0) 27.1 (29.6) 31.2 (30.3) 26.6 (28.3) 24.6 (28.0) 23.8 (27.5) 
            
Appetite loss N 571 547 506 523 491 573 541 511 523 496 
 Mean (s.d.) 6.2 (15.7) 12.0 (21.5) 6.1 (16.2) 5.5 (15.6) 6.1 (16.5) 5.1 (13.8) 11.0 (20.7) 5.5 (16.1) 5.0 (14.6) 4.4 (15.2) 
            
Constipation N 571 546 506 522 489 572 541 512 522 493 
 Mean (s.d.) 7.5 (18.2) 9.3 (19.7) 7.8 (17.9) 7.4 (18.0) 8.9 (19.0) 6.6 (16.5) 8.4 (19.7) 9.0 (20.2) 6.7 (16.4) 6.9 (17.2) 
            
Diarrhoea N 572 547 506 521 489 572 540 510 520 491 
 Mean (s.d.) 5.0 (14.3) 5.5 (15.3) 6.0 (15.5) 4.4 (13.5) 5.0 (14.8) 3.9 (12.4) 4.2 (12.0) 4.9 (15.1) 4.2 (13.6) 4.7 (15.3) 
            
Financial problems N 569 549 503 521 489 570 536 508 519 489 
 Mean (s.d.) 8.8 (21.3) 11.2 (23.2) 6.0 (16.6) 5.2 (16.9) 4.2 (14.3) 9.3 (20.2) 11.7 (22.5) 7.6 (19.3) 5.5 (16.4) 4.7 (15.5) 
            
BCTOS            
Functional status (1-4) N 458 436 418 419 400 461 438 423 423 411 
 Mean (s.d.) 1.26 (0.48) 1.34 (0.55) 1.36 (0.57) 1.27 (0.52) 1.28 (0.52) 1.23 (0.43) 1.41 (0.61) 1.45 (0.63) 1.35 (0.58) 1.30 (0.57) 
            
Cosmetic status (1-4) N 458 437 418 419 400 460 437 424 422 412 
 Mean (s.d.) 1.80 (0.59) 1.99 (0.65) 1.89 (0.59) 1.84 (0.58) 1.78 (0.58) 1.75 (0.51) 2.11 (0.61) 1.88 (0.55) 1.93 (0.62) 1.88 (0.58) 
            
Breast-specific symptoms (1-4) N 459 437 418 419 400 461 438 424 423 412 
 Mean (s.d.) 1.88 (0.71) 2.33 (0.78) 1.99 (0.75) 1.80 (0.70) 1.68 (0.69) 1.80 (0.62) 2.46 (0.81) 1.99 (0.71) 1.84 (0.69) 1.74 (0.69) 
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Body image scale (0-30) N 459 438 422 419 404 460 439 420 424 410 
 Mean (s.d.) 2.98 (4.99) 3.69 (5.54) 2.74 (4.52) 2.56 (4.71) 2.68 (4.87) 2.31 (3.81) 3.54 (4.74) 2.26 (3.70) 2.44 (4.25) 2.44 (4.40) 
            
Cancer worry scale (0-16) N 449 428 410 408 397 455 432 416 420 406 
 Mean (s.d.) 7.24 (2.57) 7.01 (2.57) 6.78 (2.27) 6.36 (2.06) 6.28 (2.16) 7.02 (2.36) 6.79 (2.22) 6.70 (2.24) 6.51 (2.32) 6.20 (2.01) 
            
Perceived risk (5 categories) N 441 418 401 403 389 437 420 409 406 396 
 Much lower 83 (19%) 77 (18%) 68 (17%) 63 (16%) 63 (16%) 89 (20%) 94 (22%) 70 (17%) 81 (20%) 75 (19%) 
 Somewhat lower 77 (17%) 69 (17%) 57 (14%) 68 (17%) 63 (16%) 80 (18%) 76 (18%) 76 (19%) 65 (16%) 64 (16%) 
 The same 207 (47%) 201 (48%) 205 (51%) 190 (47%) 194 (50%) 200 (46%) 192 (46%) 189 (46%) 201 (50%) 202 (51%) 
 Somewhat higher 61 (14%) 59 (14%) 59 (15%) 63 (16%) 57 (15%) 60 (14%) 52 (12%) 65 (16%) 54 (13%) 48 (12%) 





Supplementary Table Error! No text of specified style in document.C1. Patient characteristics at baseline for patients included in PRO analysis by Treatment 
Arm, randomisation category A only (n=377): Arm 1 [conventionally fractionated whole breast radiotherapy (WBRT) only], Arm 2 [hypofractionated WBRT 
only], Arm 3 [conventionally fractionated WBRT + tumour bed boost (TBB)], Arm 4 [hypofractionated WBRT +TBB] 
  












Age <50 73 (19%) 18 (19%) 18 (19%) 19 (20%) 18 (19%) 
 ≥50 304 (81%) 76 (81%) 75 (81%) 75 (80%) 78 (81%) 
 Region Australia, New Zealand, Singapore 268 (71%) 67 (71%) 66 (71%) 67 (71%) 68 (71%) 
 Canada 30 (8%) 7 (7%) 6 (6%) 10 (11%) 7 (7%) 
 UK, Ireland 69 (18%) 17 (18%) 18 (19%) 15 (16%) 19 (20%) 
 Europe 10 (3%) 3 (3%) 3 (3%) 2 (2%) 2 (2%) 
 Tumour Location  Upper outer quadrant 141 (37%) 32 (34%) 28 (30%) 39 (41%) 42 (44%) 
 Upper inner quadrant 39 (10%) 11 (12%) 10 (11%) 11 (12%) 7 (7%) 
 3 o'clock 20 (5%) 4 (4%) 4 (4%) 9 (10%) 3 (3%) 
 12 o'clock 37 (10%) 9 (10%) 10 (11%) 5 (5%) 13 (14%) 
 Central (within 3 cm radius of nipple) 38 (10%) 11 (12%) 10 (11%) 7 (7%) 10 (10%) 
 Lower inner quadrant 24 (6%) 4 (4%) 3 (3%) 9 (10%) 8 (8%) 
 Lower outer quadrant 31 (8%) 9 (10%) 13 (14%) 4 (4%) 5 (5%) 
 6 o'clock 19 (5%) 6 (6%) 4 (4%) 3 (3%) 6 (6%) 
 9 o'clock 28 (7%) 8 (9%) 11 (12%) 7 (7%) 2 (2%) 
 Number of re-excisions following initial surgery 0 234 (62%) 62 (66%) 56 (60%) 60 (64%) 56 (58%) 
 1 131 (35%) 28 (30%) 35 (38%) 30 (32%) 38 (40%) 
 2 8 (2%) 4 (4%) 0 (0%) 2 (2%) 2 (2%) 
 3 1 (0%) 0 (0%) 1 (1%) 0 (0%) 0 (0%) 
 At least 1 2 (1%) 0 (0%) 1 (1%) 1 (1%) 0 (0%) 
 Unknown 1 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%) 
 Sentinel Node Biopsy Yes 76 (20%) 18 (19%) 17 (18%) 19 (20%) 22 (23%) 
 No 301 (80%) 76 (81%) 76 (82%) 75 (80%) 74 (77%) 
 Axillary Dissection Yes 1 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%) 
 No 376 (100%) 94 (100%) 93 (100%) 94 (100%) 95 (99%) 
 Microscopic Tumour size less than or equal to 20mm 232 (62%) 56 (60%) 59 (63%) 59 (63%) 58 (60%) 
 21mm to 50mm 118 (31%) 27 (29%) 27 (29%) 28 (30%) 36 (38%) 
16 
 












 Greater than 50mm 24 (6%) 10 (11%) 6 (6%) 6 (6%) 2 (2%) 
 Unknown 3 (1%) 1 (1%) 1 (1%) 1 (1%) 0 (0%) 
 Months from surgery to randomisation Mean (s.d.) 1.5 (0.6) 1.5 (0.6) 1.4 (0.6) 1.5 (0.6) 1.5 (0.6) 
 Min , Max 0.3 , 2.9 0.3 , 2.6 0.3 , 2.6 0.5 , 2.9 0.4 , 2.8 
 Median (Q1 , Q3) 1.4 (1.0 , 1.8) 1.4 (1.1 , 1.9) 1.5 (1.0 , 1.8) 1.4 (1.0 , 1.8) 1.4 (1.1 , 1.8) 
 Planned endocrine therapy Yes 36 (10%) 8 (9%) 9 (10%) 9 (10%) 10 (10%) 






Supplementary Table Error! No text of specified style in document.D2. Patient characteristics at baseline for patients included in analysis by treatment arm 
(n=1147): Arm 1 [conventionally fractionated whole breast radiotherapy (WBRT) only], Arm 2 [hypofractionated WBRT only], Arm 3 [conventionally 
fractionated WBRT + tumour bed boost (TBB)], Arm 4 [hypofractionated WBRT +TBB] 












Age <50 207 (18%) 58 (19%) 44 (16%) 62 (20%) 43 (16%) 
 ≥50 940 (82%) 248 (81%) 224 (84%) 247 (80%) 221 (84%) 
 Region Australia, New Zealand, Singapore 427 (37%) 142 (46%) 70 (26%) 143 (46%) 72 (27%) 
 Canada 233 (20%) 24 (8%) 93 (35%) 27 (9%) 89 (34%) 
 UK, Ireland 220 (19%) 45 (15%) 65 (24%) 45 (15%) 65 (25%) 
 Europe 267 (23%) 95 (31%) 40 (15%) 94 (30%) 38 (14%) 
 Tumour Location  Upper outer quadrant 420 (37%) 107 (35%) 94 (35%) 117 (38%) 102 (39%) 
 Upper inner quadrant 112 (10%) 32 (10%) 28 (10%) 25 (8%) 27 (10%) 
 3 o'clock 77 (7%) 18 (6%) 14 (5%) 25 (8%) 20 (8%) 
 12 o'clock 89 (8%) 27 (9%) 23 (9%) 19 (6%) 20 (8%) 
 Central (within 3 cm radius of nipple) 156 (14%) 36 (12%) 29 (11%) 54 (17%) 37 (14%) 
 Lower inner quadrant 67 (6%) 14 (5%) 21 (8%) 16 (5%) 16 (6%) 
 Lower outer quadrant 100 (9%) 35 (11%) 27 (10%) 22 (7%) 16 (6%) 
 6 o'clock 51 (4%) 14 (5%) 13 (5%) 9 (3%) 15 (6%) 
 9 o'clock 74 (6%) 22 (7%) 19 (7%) 22 (7%) 11 (4%) 
 Number of re-excisions following initial surgery 0 777 (68%) 210 (69%) 185 (69%) 204 (66%) 178 (67%) 
 1 336 (29%) 88 (29%) 78 (29%) 89 (29%) 81 (31%) 
 2 23 (2%) 5 (2%) 2 (1%) 11 (4%) 5 (2%) 
 3 3 (0%) 1 (0%) 2 (1%) 0 (0%) 0 (0%) 
 At least 1 7 (1%) 2 (1%) 1 (0%) 4 (1%) 0 (0%) 
 Unknown 1 (0%) 0 (0%) 0 (0%) 1 (0%) 0 (0%) 
 Sentinel Node Biopsy Yes 248 (22%) 80 (26%) 47 (18%) 66 (21%) 55 (21%) 
 No 899 (78%) 226 (74%) 221 (82%) 243 (79%) 209 (79%) 
 Axillary Dissection Yes 21 (2%) 8 (3%) 0 (0%) 4 (1%) 9 (3%) 
 No 1,126 (98%) 298 (97%) 268 (100%) 305 (99%) 255 (97%) 
 Microscopic Tumour size less than or equal to 20mm 726 (63%) 177 (58%) 181 (68%) 194 (63%) 174 (66%) 
 21mm to 50mm 337 (29%) 103 (34%) 69 (26%) 91 (29%) 74 (28%) 
 Greater than 50mm 49 (4%) 15 (5%) 10 (4%) 14 (5%) 10 (4%) 
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 Unknown 35 (3%) 11 (4%) 8 (3%) 10 (3%) 6 (2%) 
 Months from surgery to randomisation Mean (s.d.) 1.4 (0.8) 1.4 (0.5) 1.4 (1.3) 1.4 (0.5) 1.5 (0.6) 
 Min , Max 0.3 , 3.0 0.3 , 2.8 0.3 , 3.0 0.3 , 2.9 0.4 , 3.0 
 Median (Q1 , Q3) 1.4 (1.0 , 1.8) 1.3 (1.0 , 1.7) 1.5 (1.1 , 1.9) 1.3 (1.0 , 1.7) 1.5 (1.1 , 2.0) 
 Planned endocrine therapy Yes 160 (14%) 23 (8%) 55 (21%) 26 (8%) 56 (21%) 






Supplementary Table E. Patient-reported outcome (PRO) compliance and missing data rates for patients recruited at non-EORTC sitesa for Breast Cancer 
Treatment Outcome Scale (BCTOS), Body Image Scale (BIS), Cancer Worry Scale (CWS); (n=968 patients recruited to the BIG 3-07 trial at non-EORTC sites 
June 2007 – 14 August 2013) 
 
PRO data collection 
time-point 
Number of patients recruited to HRQOL 
study at non-EORTC sites and still on study 
(N) at HRQOL data collection time-point 
Number compliant with planned HRQOL 
questionnaires (N) HRQOL missing data ratesb (%) 
No boost Boost Total No boost Boost Total No boost Boost Total 
BCTOS Baseline 484 483 967 459 461 920 5.2 % 4.6 % 4.9 % 
 End of RT 479 472 951 441 444 885 7.9 % 5.9 % 6.9 % 
 6 months post RT 474 462 936 426 429 855 10 % 7.1 % 8.7 % 
 12 months post RT 468 460 928 423 426 849 9.6 % 7.4 % 8.5 % 
 24 months post RT 
 
457 461 918 408 417 825 11 % 9.5 % 10 % 
 BIS Baseline 484 483 967 459 460 919 5.2 % 4.8 % 5.0 % 
 End of RT 479 472 951 441 444 885 7.9 % 5.9 % 6.9 % 
 6 months post RT 474 462 936 427 429 856 9.9 % 7.1 % 8.5 % 
 12 months post RT 468 460 928 424 426 850 9.4 % 7.4 % 8.4 % 
 24 months post RT 
 
457 461 918 409 417 826 11 % 9.5 % 10 % 
 CWS Baseline 484 483 967 452 456 908 6.6 % 5.6 % 6.1 % 
 End of RT 479 472 951 435 441 876 9.2 % 6.6 % 7.9 % 
 6 months post RT 474 462 936 419 426 845 12 % 7.8 % 9.7 % 
 12 months post RT 468 460 928 416 423 839 11 % 8.0 % 9.6 % 
 24 months post RT 457 461 918 403 413 816 12 % 10 % 11 % 
           
Perceived  Baseline 484 483 967 441 437 878 8.9 % 9.5% 9.2% 
Risk End of RT 479 472 951 418 420 838 13 % 11 % 12 % 
 6 months post RT 474 462 936 401 409 810 15 % 11 % 13 % 
 12 months post RT 468 460 928 403 406 809 14 % 12 % 13 % 
 24 months post RT 457 461 918 389 396 785 15 % 14 % 14 % 
a. The 240 substudy participants from EORTC sites completed the QLQ-C30 questionnaire only; 44 patients from European centres that were not EORTC centres 
completed all PRO questionnaires. 
b. Missing data % calcaultes as 100% minus compliance (%) with the planned PRO assessment schedule, calculated for each PRO data collection time point as the 




Supplementary Table F. Patient characteristics at baseline for patients included in analysis: boost vs no boost (n=1147a), by those with and without 2 year 
visit quality of life data 










Age <50 87 (18%) 86 (17%) 15 (18%) 19 (25%) 
 
 
≥50 405 (82%) 410 (83%) 67 (82%) 58 (75%) 
Region Australia, New Zealand, Singapore 188 (38%) 194 (39%) 24 (29%) 21 (27%) 
 Canada 105 (21%) 107 (22%) 12 (15%) 9 (12%) 
 UK, Ireland 96 (20%) 94 (19%) 14 (17%) 16 (21%) 
 
 
Europe 103 (21%) 101 (20%) 32 (39%) 31 (40%) 
Tumour location Upper outer quadrant 169 (34%) 188 (38%) 32 (40%) 31 (40%) 
 Upper inner quadrant 57 (12%) 46 (9%) 3 (4%) 6 (8%) 
 3 o’clock 27 (5%) 42 (8%) 5 (6%) 3 (4%) 
 12 o’clock 46 (9%) 37 (7%) 4 (5%) 2 (3%) 
 Central (within 3cm radius of nipple) 54 (11%) 77 (16%) 11 (14%) 14 (18%) 
 Lower inner quadrant 33 (7%) 26 (5%) 2 (2%) 6 (8%) 
 Lower outer quadrant 50 (10%) 32 (6%) 12 (15%) 6 (8%) 
 6 o’clock 22 (4%) 22 (4%) 5 (6%) 2 (3%) 
 9 o’clock 
 
34 (7%) 26 (5%) 7 (9%) 7 (9%) 
Number of re-excisions following initial 
surgery 
0 333 (68%) 327 (66%) 62 (76%) 55 (71%) 
 1 148 (30%) 150 (30%) 18 (22%) 20 (26%) 
 2 6 (1%) 14 (3%) 1 (1%) 2 (3%) 
 3 3 (1%) 0 (0%) 0 (0%) 0 (0%) 
 At least 1 2 (0%) 4 (1%) 1 (1%) 0 (0%) 
 Unknown 
 
0 (0%) 1 (0%) 0 (0%) 0 (0%) 
Sentinel Node Biopsyb Yes 103 (21%) 98 (20%) 24 (29%) 23 (30%) 














Axillary Dissection Yes 6 (1%) 12 (2%) 2 (2%) 1 (1%) 
 No 486 (99%) 484 (98%) 80 (98%) 76 (99%) 
 
Microscopic tumour size Less than or equal to 20mm 309 (63%) 316 (64%) 49 (60%) 52 (68%) 
 21mm to 50mm 152 (31%) 148 (30%) 20 (24%) 17 (22%) 
 Greater than 50mm 20 (4%) 19 (4%) 5 (6%) 5 (6%) 
 Unknown 
 
11 (2%) 13 (3%) 8 (10%) 3 (4%) 
Months from surgery to randomisation Mean (s.d.) 1.4 (1.0) 1.4 (0.5) 1.4 (0.5) 1.5 (0.6) 
 Min , Max 0.3 , 3.0 0.3 , 3.0 0.5 , 2.7 0.3 , 2.8 
 Median (Q1 , Q3) 1.4 (1.0 , 1.8) 1.4 (1.0 , 1.8) 1.3 (1.0 , 1.7) 1.4 (1.0 , 1.8) 
 
Planned endocrine therapy Yes 64 (13%) 69 (14%) 14 (17%) 13 (17%) 
 
 
No 428 (87%) 427 (86%) 68 (83%) a 83%) 
a. These 1147 patients completed measures at baseline and at least one other time point reported. 
b. P-value for test of association between having or not having 2 year data and sentinel node biopsy was 0.009 (Pearson chi-squared test) 
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Supplementary Table G.Error! No text of specified style in document. Patient-reported outcome (PRO) 
scores a3t baseline and two years, by sentinel node biopsy at baseline (Yes, No), for patients who 
completed PRO questionnaires are baseline and two years (n=988) 
  Sentinel Node Biopsy Wilcoxon Test 
P-Value   Total  No Yes  
EORTC QLQ-C30 mean (SD)  (N=988) (N=787) (N=201)  
Physical functioning  Baseline 91.91 (11.68) 92.39 (11.55) 90.03 (12.01) 0.001 
(0-100, higher indicates better function) 2 years 90.78 (13.57) 91.22 (13.27) 89.09 (14.60) 0.042 
Difference 
 
-1.20 (12.37) -1.27 (12.52) -0.94 (11.78) 0.88 
Fatigue  Baseline 19.03 (17.89) 18.50 (17.55) 21.06 (19.03) 0.088 
(0-100, higher indicates more fatigue) 2 years 18.35 (20.22) 17.75 (19.62) 20.67 (22.27) 0.13 
Difference -0.69 (20.51) -0.77 (19.98) -0.39 (22.53) 0.78 
Breast Cancer Treatment Outcome Scale mean (SD) (N=819) (N=698) (N=121)  
Functional status  Baseline 1.24 (0.45) 1.20 (0.41) 1.44 (0.57) <0.001 
(1-4, higher indicates greater perceived 
difference between the treated and 
untreated breast and area)  
2 years 1.29 (0.55) 1.27 (0.52) 1.44 (0.65) <0.001 
Difference 
 
0.05 (0.58) 0.06 (0.57) 0.00 (0.64) 0.32 
Cosmetic status  Baseline 1.76 (0.54) 1.74 (0.53) 1.88 (0.55) <0.001 
(1-4, higher indicates greater perceived 
difference between the treated and 
untreated breast and area) 
2 years 1.83 (0.58) 1.81 (0.58) 1.99 (0.57) <0.001 
Difference 
 
0.07 (0.56) 0.07 (0.56) 0.10 (0.58) 0.77 
Breast-specific pain  Baseline 1.83 (0.66) 1.82 (0.64) 1.87 (0.74) 0.65 
(1-4, higher indicates greater perceived 
difference between the treated and 
untreated breast and area) 
2 years 1.71 (0.69) 1.71 (0.70) 1.74 (0.67) 0.42 
Difference -0.12 (0.75) -0.11 (0.75) -0.14 (0.79) 0.60 
Body Image Scale mean (SD)  (N=820) (N=699) (N=121)  
(0-30, higher indicates more 
symptoms/distress) 
 
Baseline 2.50 (4.35) 2.42 (4.39) 2.96 (4.11) 0.006 
2 years 2.56 (4.64) 2.45 (4.54) 3.19 (5.15) 0.090 
Difference 0.06 (4.24) 0.03 (4.18) 0.23 (4.57) 0.71 
Cancer Worry Scale mean (SD)  (N=810) (N=691) (N=119)  
(0-16, higher indicates more more cancer 
worry) 
 
Baseline 7.07 (2.42) 7.05 (2.34) 7.18 (2.86) 0.74 
2 years 6.24 (2.09) 6.20 (2.06) 6.46 (2.24) 0.26 
 Difference -0.82 (2.20) -0.84 (2.20) -0.71 (2.21) 0.40 
Perceived risk (5 categories)      
Baseline Much lower 163 (21%) 137 (20%) 26 (23%) 0.72 
 Somewhat lower 141 (18%) 125 (19%) 16 (14%)  
 The same 354 (45%) 305 (46%) 49 (44%)  
 Somewhat higher 106 (14%) 88 (13%) 18 (16%)  
 Much higher 
 
18 (2%) 15 (2%) 3 (3%)  
2 years  Much lower 138 (18%) 113 (17%) 25 (22%) 0.70 
 Somewhat lower 127 (16%) 114 (17%) 13 (12%)  
 The same 396 (50%) 340 (51%) 56 (50%)  
 Somewhat higher 105 (13%) 88 (13%) 17 (15%)  
 Much higher 
 
19 (2%) 18 (3%) 1 (1%)  
Difference -4 3 (0%) 3 (0%) 0 (0%) 0.62 
 -3 5 (1%) 3 (0%) 2 (2%)  
 -2 51 (7%) 41 (6%) 10 (9%)  
 -1 119 (16%) 102 (16%) 17 (16%)  
 0 360 (47%) 315 (48%) 45 (42%)  
 1 139 (18%) 117 (18%) 22 (21%)  
 2 73 (10%) 63 (10%) 10 (9%)  


















scale Perceived risk 
Baseline measures         
Fatigue 1.00 -0.50 0.36 0.20 0.33 0.25 0.21 0.08 
Physical functioning -0.50 1.00 -0.34 -0.11 -0.17 -0.15 -0.12 -0.06 
Functional status (1-4) 0.36 -0.34 1.00 0.24 0.39 0.27 0.25 0.07 
Cosmetic status (1-4) 0.20 -0.11 0.24 1.00 0.46 0.52 0.20 0.16 
Breast-specific pain (1-4) 0.33 -0.17 0.39 0.46 1.00 0.35 0.29 0.13 
Body image scale (0-30) 0.25 -0.15 0.27 0.52 0.35 1.00 0.36 0.16 
Cancer worry scale (0-16) 0.21 -0.12 0.25 0.20 0.29 0.36 1.00 0.30 
Perceived risk (5 categories) 0.08 -0.06 0.07 0.16 0.13 0.16 0.30 1.00 
End of RT         
Fatigue 1.00 -0.62 0.45 0.35 0.47 0.32 0.21 0.07 
Physical functioning -0.62 1.00 -0.52 -0.29 -0.36 -0.27 -0.15 -0.07 
Functional status (1-4) 0.45 -0.52 1.00 0.36 0.40 0.32 0.23 0.05 
Cosmetic status (1-4) 0.35 -0.29 0.36 1.00 0.60 0.50 0.25 0.15 
Breast-specific pain (1-4) 0.47 -0.36 0.40 0.60 1.00 0.37 0.23 0.13 
Body image scale (0-30) 0.32 -0.27 0.32 0.50 0.37 1.00 0.42 0.18 
Cancer worry scale (0-16) 0.21 -0.15 0.23 0.25 0.23 0.42 1.00 0.30 
Perceived risk (5 categories) 0.07 -0.07 0.05 0.15 0.13 0.18 0.30 1.00 
6 months         
Fatigue 1.00 -0.61 0.40 0.21 0.35 0.25 0.26 0.10 
Physical functioning -0.61 1.00 -0.45 -0.23 -0.28 -0.23 -0.22 -0.08 
Functional status (1-4) 0.40 -0.45 1.00 0.29 0.38 0.27 0.26 0.05 
Cosmetic status (1-4) 0.21 -0.23 0.29 1.00 0.52 0.55 0.31 0.17 
Breast-specific pain (1-4) 0.35 -0.28 0.38 0.52 1.00 0.38 0.38 0.13 
Body image scale (0-30) 0.25 -0.23 0.27 0.55 0.38 1.00 0.38 0.17 
Cancer worry scale (0-16) 0.26 -0.22 0.26 0.31 0.38 0.38 1.00 0.27 















scale Perceived risk 
12 months         
Fatigue 1.00 -0.61 0.34 0.22 0.36 0.26 0.26 0.06 
Physical functioning -0.61 1.00 -0.40 -0.19 -0.29 -0.24 -0.15 0.02 
Functional status (1-4) 0.34 -0.40 1.00 0.30 0.40 0.29 0.24 0.06 
Cosmetic status (1-4) 0.22 -0.19 0.30 1.00 0.47 0.51 0.25 0.16 
Breast-specific pain (1-4) 0.36 -0.29 0.40 0.47 1.00 0.33 0.31 0.12 
Body image scale (0-30) 0.26 -0.24 0.29 0.51 0.33 1.00 0.39 0.13 
Cancer worry scale (0-16) 0.26 -0.15 0.24 0.25 0.31 0.39 1.00 0.29 
Perceived risk (5 categories) 0.06 0.02 0.06 0.16 0.12 0.13 0.29 1.00 
2 years         
Fatigue 1.00 -0.60 0.34 0.23 0.32 0.29 0.26 0.08 
Physical functioning -0.60 1.00 -0.39 -0.17 -0.21 -0.18 -0.18 -0.05 
Functional status (1-4) 0.34 -0.39 1.00 0.28 0.37 0.33 0.24 0.03 
Cosmetic status (1-4) 0.23 -0.17 0.28 1.00 0.41 0.55 0.19 0.09 
Breast-specific pain (1-4) 0.32 -0.21 0.37 0.41 1.00 0.38 0.27 0.11 
Body image scale (0-30) 0.29 -0.18 0.33 0.55 0.38 1.00 0.37 0.10 
Cancer worry scale (0-16) 0.26 -0.18 0.24 0.19 0.27 0.37 1.00 0.26 



















 EORTC QLQ-C30        
Physical functioning N 1,147 427 233 220 267 0.011 
 Mean (s.d.) 91.7 (12.1) 93.0 (10.6) 91.6 (10.7) 91.4 (12.3) 89.7 (14.7)  
 Fatigue N 1,146 426 233 220 267 0.24 
 Mean (s.d.) 19.3 (18.6) 17.8 (16.7) 19.4 (19.0) 18.6 (18.2) 22.0 (21.2)  
BCTOS        
Functional status (1-4) N 919 427 233 216 43 0.21 
 Mean (s.d.) 1.24 (0.45) 1.22 (0.44) 1.22 (0.42) 1.30 (0.52) 1.22 (0.37)  
        
Cosmetic status (1-4) N 918 425 233 217 43 0.008 
 Mean (s.d.) 1.77 (0.55) 1.77 (0.52) 1.74 (0.54) 1.77 (0.59) 2.05 (0.61)  
        
Breast-specific  N 920 427 233 217 43 0.46 
symptoms (1-4) Mean (s.d.) 1.84 (0.67) 1.83 (0.68) 1.81 (0.63) 1.86 (0.68) 1.97 (0.68)  
        
Body image scale (0-30) N 919 426 233 217 43 <0.001 
 Mean (s.d.) 2.64 (4.45) 2.12 (3.94) 2.90 (4.33) 3.03 (5.22) 4.54 (4.92)  
        
Cancer worry scale (0-16) N 908 425 224 216 43 0.023 
 Mean (s.d.) 7.13 (2.47) 7.01 (2.38) 6.88 (2.35) 7.57 (2.72) 7.30 (2.42)  
 
Perceived risk (5 categories) 
N 878 412 217 208 41 0.35 
 Much lower 172 (20%) 81 (20%) 53 (24%) 33 (16%) 5 (12%)  
 Somewhat lower 157 (18%) 67 (16%) 40 (18%) 43 (21%) 7 (17%)  
 The same 407 (46%) 193 (47%) 90 (41%) 98 (47%) 26 (63%)  
 Somewhat 
higher 
121 (14%) 58 (14%) 32 (15%) 28 (13%) 3 (7%)  
 Much higher 21 (2%) 13 (3%) 2 (1%) 6 (3%) 0 (0%)  
EORTC QLQ-C30: A high score for physical functioning represents a high level of functions, but a high score fatigue represents a more fatigue.  
BCTOS: A higher score indicates greater perceived difference between the treated and untreated breast and area. 
BIS: A higher score represents more symptoms/distress.  
CWS: A higher cancer worry scale indicates more cancer worries. 
Perceived risk:  In your opinion, compared with other women your age who have DCIS, what are your chances of getting invasive breast cancer






Total number of 
DCIS patients per 
site Principal Investigator
Peter MacCallum Cancer Centre Australia 83% 90
Boon H Chua
Claire Phillips
Radiation Oncology Services Mater Centre Australia 87% 78 Guy Bryant
Arnhems Radiotherapeutisch Instituut - ARTI Netherlands 83% 66 Helen Westenberg
Sheffield Teaching Hospitals UK 68% 66 O P Purohit
Westmead Hospital Australia 84% 63 Verity Ahern
St George Hospital Australia 89% 44 Peter Graham
Cancer Care Manitoba Canada 81% 43 Mohamed Akra
SLRON at SLH SJH and Beaumont Ireland 63% 38 Orla McArdle
Calvary Mater Newcastle Australia 91% 34
Peter O'Brien
Jane Ludbrook
Princess Alexandra Hospital Australia 75% 32 Jennifer Harvey
University Medical Centre Groningen Netherlands 74% 31 John H. Maduro
Chr De Grenoble - La Tronche France 77% 30 Isabelle Gabelle-Flandin
Cliniques Universitaires St Luc Belgium 67% 30 Carine Kirkove
Edinburgh Western General Hospital UK 59% 29 Carolyn Bedi
University Hospital Galway Ireland 77% 26 Joseph Martin
Notre Dame Hospital Canada 96% 25 Tony Vu
McGill University Department of Oncology Canada 84% 25 Theirry Muanza
Royal Surrey County Hospital UK 64% 25 Anthony Neal
Centre Antoine Lacassagne France 67% 24
Adel Courdi
Juliette Thariat
Odette Cancer Centre - Canada 87% 23 Eileen Rakovitch
Leiden University Medical Centre Netherlands 73% 22
Laurien Daniels
Marjan van Hezewijk
Nova Scotia Cancer Centre Canada 95% 21 Wlasyslawa Cwajna
Onze Lieve Vrouw Ziekenhuis Belgium 81% 21 Adelheid Roelstraete
Maastricht Radiation Oncology - Maastro Clinic Netherlands 67% 21 Angela van Baardwijk
Cancer Institute Antoni Van Leeuwenhoekziekenhuis Netherlands 75% 20 Nicola Russel
Princess Margaret Hospital Canada 65% 20
Anne Koch
Jennifer Croke
Royal Marsden Hospital UK 72% 18 Imogen Locke





Sir Charles Gairdner Hospital Australia 75% 16
David Joseph
Mandy Taylor
ZNA Middelheim Belgium 56% 16 Sabine Vanderkam
National University Hospital Singapore 100% 15
Tony Woo 
Johann Tang
Hopital Maisonneuve-Rosemont Canada 100% 15 Michael Yassa
Vancouver Island Cancer Centre Canada 93% 15 Elaine Wai
The Townsville Hospital Australia 87% 15 Susan Hewitt
Allan Blair Cancer Centre Canada 80% 15 Shazia Mahmood
Cork University Hospital Ireland 47% 15
Jennifer Gilmore
Bolante Ofi
University Hospitals Bristol NHS Foundation Trust UK 33% 15 Amit Bahl
London Regional Cancer Program Canada 100% 14
Olga Vujovic
Edward Yu
Saskatoon Cancer Centre Canada 64% 14 Duc Le
Jurvanski Cancer Centre Canada 21% 14 Iwa Kong
BCCA Vancouver Centre Canada 85% 13 Alan Nichol
Academisch Medisch Centrum Netherlands 69% 13 N. Bijker
Liverpool Hospital Australia 62% 13 Geoff Delaney




Royal Perth Hospital Australia 100% 12 Dr Margaret Latham
Southend University Hospital UK 58% 12 Hafiz Algurafi
Brust-Zentrum Zurich-Seefeld Switzerland 100% 11 Christoph Tausch
Toowoomba Cancer Research Centre Australia 91% 11
Eric Khoo
Sam Leung
Alfred Hospital Australia 73% 11
Karen Taylor
Sasha Senthi
University Hospital Birmingham NHS Foundation Trust UK 73% 11 Andrea Stevens
Lincoln County Hospital UK 64% 11 Abhro Chaudhuri 
Charing Cross Hospital UK 46% 11 Susan Cleator
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University Hospital of North Staffordshire UK 27% 11 Adrian Murray Brunt
Christchurch Hospital New Zealand 100% 10 Scott Babington
Genesis Cancer Care - Tugun Australia 90% 10 David Christie
Kantonsspital Graubunden Switzerland 70% 10 Daniel Zwahlen
University Hospital Basel Switzerland 78% 9 Ulrich Schratzenstaller
Centre Hospitalier Universitaire de Sherbrooke Canada 67% 9 Laurence Masson
James Cook University Hospital UK 67% 9 Nicola Storey
Saint John Regional Hospital Canada 75% 8 Eshwar Kumar
Ipswich Hospital UK 75% 8 Liz Sherwin
Algemeen Ziekenhuis Sint-Augustinus Belgium 63% 8 Reinhilde Weytjens
Aberdeen Royal Infirmary UK 63% 8 Sharma Ravi
Nottingham University Hospitals UK 38% 8 Patricia Lawton





Thunder Bay Regional Health Sciences Centre Canada 100% 7 Margaret Anthes
Kantonsspital Munsterlingen Switzerland 71% 7 Christiane Reuter
New Cross Hospital Wolverhampton UK 57% 7 Laura Pettit
Mid Staffordshire NHS Foundation Trust, Stafford Hospital UK 43% 7 Laura Pettit
Perth Radiation Oncology Australia 100% 6 Yvonne Zissiadis
Auckland Hospital New Zealand 100% 6 Christine Elder
Medisch Centrum Haaglanden Westeinde Netherlands 100% 6 Antoinette Verbeek-de Kanter
Leon Richard Oncology Centre Canada 83% 6 Andree Lirette
Kantonsspital St. Gallen Switzerland 80% 5 Ludwig Plasswilm
Sandwell and West Birmingham Hospitals NHS Trust UK 80% 5
David Spooner
Fiona Hoar
Southern Interior Canada 60% 5 Islam Mohamed
Inselspital Bern Switzerland 60% 5 Kristina Lossl
Essex County Hospital, Colchester UK 60% 5 Vivienne Loo
Istituto Oncologico della Svizzera Italiana (IOSI) Switzerland 40% 5 Antonella Richetti
Dumfries & Galloway Royal Infirmary UK 40% 5
Tamasin Evans
Aisling Hennessy
Lakeridge Health Oshawa Canada 25% 5 Medhat El-Mallah
Royal Hobart Hospital Australia 100% 4
Marketa Skala
Raef Awad
L'Hotel-Dieu de Quebec Canada 100% 4 Isabelle Germain
Hopital de Jolimont Belgium 100% 4 Carine Mitine
Universitair Ziekenhuis Brussel Belgium 100% 4 Hilde Van Parijs
Worcestershire Acute Hosapitals NHS Trust, Kidderminster NHS 
Treatment Centre UK 100% 4 Mark Churn
Warwick Hospital UK 25% 4 Nawaz Walji
Barwon Health Australia 100% 3 Michael Francis
AZ Groeninghe – Campus Maria’s Voorzienigheid Belgium 100% 3 Karin Stellamans
Klinik Hirslanden Switzerland 100% 3 Gunther Gruber
Fondazione Salvatore Maugeri Pavia Italy 100% 3 Giovanni Ivaldi
Beatson West of Scotland Cancer Centre UK 100% 3 Abdulla Alhasso
Royal Brisbane and Womens Hospital Australia 67% 3 Lizbeth Kenny
Nepean Cancer Care Centre Australia 67% 3 Ken Tiver
Kings Mill Hospital, Nottingham UK 33% 3 Matthew Griffin
Royal North Shore Australia 100% 2 Gillian Lamoury
Centro Di Riferimento Oncologico Aviano Italy 100% 2 Marco Trovo
Basildon Hospital UK 100% 2 Hafiz Algufarfi 
Arden Cancer Research Centre Coventry UK 100% 2 Nawaz Walji
Genesis Cancer Care - Wesley Australia 50% 2
Minjae Lah
David Christie
Royal Alexandra Hospital, Paisley UK 50% 2 Abdulla Alhasso
Royal Adelaide Hospital Australia 100% 1 Scott Carruthers
Campbelltown Hospital Australia 100% 1 George Papadatos
ISALA Klinieken Netherlands 100% 1 Gabriel Paardekooper
Pilgrim Hospital UK 100% 1 Abhro Chaudhuri
Queen's Hospital Burton UK 100% 1 Mojca Persic
Churchill Hospital Oxford UK 100% 1 Bernadette Lavery 
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